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Abstract 
Objective 
Simple, rapid, non hazardous, accurate, non expensive and precise derivative 
spectrophotometric method was developed and optimized for analysis of 
mebendazole, tinidazole, albendazole metronidazole, metronidazole benzoate 
and combination of hydrochlorothiazide and amiloride hydrochloride  in 
pharmaceutical formulations as their official method either HPLC which is 
expensive or non aqueous titration which is hazardous and not accurate. 
The work included the study of the expected interference of pharmaceutical 
excipients, used in these formulations by choice of different brand formulations. 
Methodology  
Derivative spectrophotometry techniques were applied for analysis of these 
formulations, the derivative procedures were based on the linear relationship 
between the concentrations of pharmaceutical substances and the amplitude of 
derivative peaks. 
The derivative methods were compared with the official high performance 
liquid chromatography methods. 
Results 
The 2nd derivative spectrum of mebendazole standard solution (in isoprpanol at 
271 nm) and albendazole standard solution (in 0.1M methanolic HCl at 330 nm) 
gave linearity with correlation coefficient of 0.998 in the concentration range 5-
50µg/ml. 
The 1st derivative spectrum of tinidazole standard solution  
(in methanol at 300 nm) and metronidazole standard solution (in water at 295 
nm) gave linearity with correlation coefficient of 0.999 in the concentration 
range 5-50µg/ml and 2.5-40µg/ml respectively. 
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The 1st derivative spectrum of metronidazole benzoate standard (in methanol 
at290 nm) gave linearity with correlation coefficient of 0.997 in the 
concentration range 10-50µg/ml.  
The zero absorption (at 364 nm) and the 2nd derivative (at 289 nm) 
 spectra of amiloride HCl and hydrochlorothiazide respectively in combination 
gave linearity with correlation coefficient of 0.999 at concentration 1-5 µg /ml 
of amiloride HCl and 10-50 µg /ml for hydrochlorothiazide  
These methods were validated and compared with high performance liquid 
chromatography methods for each formulation. The precision of the developed 
methods were predicted by calculating the F- value between the developed 
methods and the HPLC methods. All the calculated F-values were found less 
than the tabulated ones which indicated the precision of the developed method.   
The accuracy of the prescribed methods was evaluated using t-tests. All the 
calculated t-values are less than the tabulated ones, so these methods seem to be 
of high accuracy.  
The developed methods were repeatable and reproducible as shown by 
comparison of the relative standard deviation (RSD) for one day results and 
between day's results. These were found to be less than 2%.   
Conclusion 
The developed methods were successfully applied in the quantitative assay of 
commercial tablets and oral suspensions, results of analysis of the different 
dosage forms by the developed derivative methods were found to be similar to 
those obtained by the official methods.  
The developed methods are simple, rapid and of high accuracy. 
They recommended for use in routine analysis. 
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  ﻠﺺ اﻻﻃﺮوﺣﻪﺴﺘﺨﻣ
 
  :اﻷهﺪاف
 اﻟﻤﺒﻨﺪازول واﻟﺘﻴﻨﺪازول واﻟﺒﻨﺪازول واﻟﻤﺘﺮﻧﻴﺪازول  ﺑﺎﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ ﻟﺘﺤﻠﻴﻞ  ﺗﺤﺎﻟﻴﻞاﺳﺘﺤﺪاث ﻃﺮق
 ﻓﻲ أﺷﻜﺎﻟﻬﺎ أﻟﺼﻴﺪﻻﻧﻴﻪ ﺰوات واﻻﻣﻴﺮوﻻﻳﺪ هﺎﻳﺪروآﻠﻮرﻳﺪ واﻟﻬﺎﻳﺪروآﻠﻮروﺳﺎﻳﺰاﻳﺪواﻟﻤﻴﺘﺮوﻧﻴﺪازول ﺑﻨ
  (.اﻗﺮاص وﻣﻌﻠﻘﺎت)اﻟﻤﺨﺘﻠﻔﺔ 
  .ﻣﻦ ﻣﺼﺎدر ﻣﺨﺘﻠﻔﺔ ﺗﺄﺛﻴﺮ اﻟﻤﻮاد اﻟﻤﻀﺎﻓﺔ أﻟﻤﺴﺘﺨﺪﻣﻪ ﻓﻲ ﺗﺮآﻴﺐ ﺗﻠﻚ اﻟﻤﺴﺘﺤﻀﺮات دراﺳﺔ
  :ﻣﻨﻬﺠﻴﺔ اﻟﺒﺤﺚ
  أﻟﺨﻄﻴﻪ ﺑﻴﻦ ﺗﺮآﻴﺰ ﻪﻋﻠﻰ  اﻟﻌﻼ ﻗ واﻋﺘﻤﺪت أﻟﻄﺮﻳﻘﻪ ﺗﻢ اﺳﺘﺨﺪام اﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ ﻟﺘﺤﻠﻴﻞ  ﺗﻠﻚ اﻟﻌﻘﺎرات
  .اﻟﻤﻮاد اﻟﻔﺎﻋﻠﺔ  واﻻﻣﺘﺼﺎﺻﻴﺔ
 ﺗﻤﺖ ﻣﻘﺎرﻧﺔ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﺑﺎﻟﻄﺮق أﻟﻤﺴﺘﺤﺪﺛﻪ ﻣﻊ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﺑﺎﻟﻄﺮق أﻟﺪﺳﺘﻮرﻳﻪ 
  :  اﻟﻨﺘﺎﺋﺞ
  .   ﻟﻜﻞ اﻟﻤﺴﺘﺤﻀﺮات ﻋﻼﻗﻪ ﺧﻄﻴﻪ ﻗﻮﻳﻪاﻋﻄﺖ اﻟﻄﺮق اﻟﻤﺴﺘﺤﺪﺛﻪ
ﻃﻮل اﻟﻤﻮﺟﻪ  ﻋﻨﺪ)واﻟﺒﻨﺪازول (  ﻧﺎﻧﻮﻣﻴﺘﺮ172ﻃﻮل اﻟﻤﻮﺟﻪ   ﻋﻨﺪ)اﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ اﻟﺜﺎﻧﻲ ﻟﻠﻤﺒﻨﺪازول 
واﺛﺒﺘﺖ اﻟﻨﺘﺎﺋﺞ وﺟﻮد ﺗﻨﺎﺳﺐ ( 899.0) ووﺟﺪ ﻣﻌﺎﻣﻞ  اﻻرﺗﺒﺎط أﻟﺨﻄﻴﻪاﻋﻄﻰ ﻋﻼﻗﺔ (  ﻧﺎﻧﻮﻣﻴﺘﺮ 033
  .ﻣﻞ/ ﻣﻴﻜﺮوﺟﺮام05-5ﻃﺮدي ﻓﻲ اﻟﻤﺪى 
ﻋﻨﺪ ﻃﻮل اﻟﻤﻮﺟﻪ )وﻟﻠﻤﻴﺘﺮوﻧﻴﺪازول ( ﻧﺎﻧﻮﻣﻴﺘﺮ 003ﻋﻨﺪ ﻃﻮل اﻟﻤﻮﺟﻪ )اﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ اﻷول ﻟﻠﺘﻴﻨﺪازول 
ﻣﻞ / ﻣﻴﻜﺮوﺟﺮام05-5ﻓﻲ اﻟﻤﺪى (  999.0)اﻋﻄﻰ ﻋﻼﻗﺔ ﺧﻄﻴﺔ ﺑﻤﻌﺎﻣﻞ ارﺗﺒﺎط (  ﻧﺎﻧﻮﻣﻴﺘﺮ092
  .ﻟﻠﻤﻴﺘﺮوﻧﻴﺪازول.  ﻣﻞ/ ﻣﻴﻜﺮوﺟﺮام 05 -5.2ﻟﻠﺘﻴﻨﺪازول و 
واﻋﻄﺖ ﻃﺮﻳﻘﺔ اﻟﺘﺤﻠﻴﻞ اﻟﻤﺴﺘﺤﺪﺛﻪ ﻟﻌﻘﺎر اﻟﻤﻴﺘﺮوﻧﻴﺪازول ﺑﻨﺰوات ﻋﻼﻗﻪ ﺧﻄﻴﻪ ﺑﻴﻦ اﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ اﻻول 
  .ﻣﻞ/ ﻣﻴﻜﺮوﺟﺮام 05-5ز ﻓﻲ اﻟﻤﺪى (. 799.0)ﻞ ارﺗﺒﺎط ﺑﻤﻌﺎﻣ  ﻧﺎﻧﻮﻣﻴﺘﺮ092ﻋﻨﺪ ﻃﻮل اﻟﻤﻮﺟﻪ 
واﻟﻤﺸﺘﻖ اﻟﻄﻴﻔﻲ اﻟﺜﺎﻧﻲ (  ﻧﺎﻧﻮﻣﻴﺘﺮ463ﻃﻮل اﻟﻤﻮﺟﻪ   ﻋﻨﺪ)اﻻﻣﺘﺼﺎﺻﻴﺔ ﻟﻼﻣﻴﻠﻮراﻳﺪ هﺎﻳﺪروآﻠﻮرﻳﺪ 
اﻋﻄﻮا ﻋﻼﻗﺔ ﺧﻄﻴﺔ ﺑﻤﻌﺎﻣﻞ ارﺗﺒﺎط   (  ﻧﺎﻧﻮﻣﻴﺘﺮ982ﻃﻮل اﻟﻤﻮﺟﻪ   ﻋﻨﺪ)ﻟﻠﻬﺎﻳﺪروآﻠﻮروﺳﺎﻳﺰاﻳﺪ 
ﻣﻞ / ﻣﺎﻳﻜﺮوﺟﺮام05-01ﻞ  ﻟﻼﻣﻴﻠﻮراﻳﺪ هﺎﻳﺪروآﻠﻮرﻳﺪ وﻣ/ ﻣﺎﻳﻜﺮوﺟﺮام5-1ﻋﻨﺪ اﻟﺘﺮآﻴﺰ 999.0
 ﻟﻠﻬﺎﻳﺪروآﻠﻮروﺳﺎﻳﺰاﻳﺪ
  ق أﻟﺪﺳﺘﻮرﻳﻪ ﻄﺮﺎﻟ اﻟﻤﺴﺘﺤﺪﺛﻪ ﻣﻊ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﻟﻠﻤﺴﺘﺤﻀﺮات ﺑقﺗﻤﺖ ﻣﻘﺎرﻧﺔ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﺑﺎﻟﻄﺮ
  ﺑﻴﻦ ﻧﺘﺎﺋﺞ اﻟﻄﺮﻳﻘﺘﻴﻦ  ﺣﻴﺚ وﺟﺪت ﻓﻲ آﻞ Fﻗﻴﻤﺔ  ﺑﺤﺴﺎب(   ﺑﺎﻟﻀﻐﻂ اﻟﻌﺎﻟﻲاﻟﻜﺮوﻣﺎﺗﻮﻏﺮاﻓﻲ اﻟﻔﺼﻞ )
 .اﻟﻤﺠﺪوﻟﻪ ﻣﻤﺎ ﻳﺆآﺪ دﻗﺔ اﻟﻄﺮﻳﻘﻪ اﻟﻤﺴﺘﺤﺪﺛﻪ اﻗﻞ ﻣﻦ ﺗﻠﻚ اﻟﻘﻴﻢ  اﻟﻤﺴﺘﺤﻀﺮات
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  وﺗﻢ اﺟﺮاء اﻟﺘﺤﺎﻟﻴﻞ ﻋﺪة ﻣﺮات ﻓﻲ اﻟﻴﻮم اﻟﻮاﺣﺪ وﻓﻲ اﻳﺎم ﻣﺨﺘﻠﻔﻪ ﻟﻤﻌﺮﻓﺔ ﻣﺪى ﺗﻮاﺗﺮ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﺑﺘﻠﻚ
  .اﻟﺘﻲ وﺟﺪت اﻗﻞ ﻣﻦ ﺗﻠﻚ اﻟﻤﺠﺪوﻟﻪ ﻣﻤﺎ ﻳﺆآﺪ ﺗﻮاﺗﺮ ﻧﺘﺎﺋﺞ اﻟﺘﺤﺎﻟﻴﻞ ﺑﺘﻠﻚ اﻟﻄﺮق tاﻟﻄﺮق وذﻟﻚ ﺑﺤﺴﺎب 
أﺛﺒﺘﺖ اﻟﺪراﺳﺔ ﺑﺎن  اﻟﻄﺮق اﻟﻤﺴﺘﺤﺪﺛﻪ هﻲ ﻃﺮق ذات ﻣﺼﺪاﻗﻴﻪ  وﺗﻌﻄﻲ ﻧﻔﺲ اﻟﻨﺘﺎﺋﺞ ﺑﺘﻜﺮارهﺎ وذﻟﻚ 
  .ﻟﻜﻞ اﻟﻤﺴﺘﺤﻀﺮات% 2ﺑﺘﺤﺪﻳﺪ درﺟﺔ اﻻﻧﺤﺮاف اﻟﻘﻴﺎﺳﻲ واﻟﺘﻲ ﻟﻢ ﺗﺘﻌﺪى 
اﺳﺘﺨﺪﻣﺖ اﻟﻄﺮق اﻟﻤﺴﺘﺤﺪﺛﻪ ﻓﻲ اﻟﺒﺤﺚ اﻟﺤﺎﻟﻲ ﺑﻨﺠﺎح ﺗﺎم ﻓﻲ اﻟﺘﺤﻠﻴﻞ اﻟﻜﻤﻲ ﻟﻤﺴﺘﺤﻀﺮات ﺗﺠﺎرﻳﻪ 
  .ﺼﺎدر ﻣﺨﺘﻠﻔﺔﻣﻦ ﻣ( اﻗﺮاص وﻣﻌﻠﻘﺎت)
  :أﻟﺨﻼﺻﻪ
ﺧﻠﺼﺖ اﻟﺪراﺳﻪ اﻟﻰ ان ﻧﺘﺎﺋﺞ اﻟﺘﺤﺎﻟﻴﻞ ﺑﺎﻟﻄﺮق اﻟﻤﺴﺘﺤﺪﺛﻪ ﻟﻼدوﻳﻪ ﻣﻮﺿﻮع اﻟﺒﺤﺚ ﻓﻲ اﻻﺷﻜﺎل اﻟﺼﻴﺪﻻﻧﻴﻪ 
 اﻟﻤﺨﺘﻠﻔﻪ ﻻﺗﺨﺘﻠﻒ ﻋﻦ ﺗﻠﻚ اﻟﻤﺘﺤﺼﻞ ﻋﻠﻴﻬﺎ ﺑﺎﻟﻄﺮق اﻟﺪﺳﺘﻮرﻳﻪ اﻟﻤﻌﺘﻤﺪﻩ ﻋﻠﻴﻪ ﻓﺎن اﻟﻄﺮق اﻟﻤﺴﺘﺤﺪﺛﻪ ﺗﻌﺘﺒﺮ 
  ﻓﻲ ﻣﻌﺎﻣﻞ ﺿﺒﻂ ﻲ ﻣﻦ اﺳﺘﺨﺪاﻣﻬﺎ ﻓﻲ اﻟﺘﺤﻠﻴﻞ اﻟﺮوﺗﻴﻨﻏﻴﺮ ﻣﻜﻠﻔﻪ وﺳﺮﻳﻌﻪ وﺑﺴﻴﻄﻪ ﻣﻤﺎ ﻳﻤﻜﻦاﻻﻓﻀﻞ ﻻﻧﻬﺎ
 اﻟﺠﻮدﻩ
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Abbreviation: 
AAS; Atomic Absorption Spectrophotometery  
AES; Atomic Emission Spectrophotometery 
ASTM; American Society for Testing and Material 
B. No: Batch Number  
BP: British Pharmacopeia 
CV: Coefficient of Variation  
Exp. Date: Expire Date 
FDA; Food and Drug Administration  
FID; flame ionization detector 
GC; Gas Chromatography 
GMP; Good Manufacturing Practice 
HPLC; High Performance Liquid Chromatography 
ICH; International Conference on Harmonization  
ISO; International Organization for Standardization 
IUPAC; International Union of Pure and Applied Chemistry 
Mf. Date: Manufacture Date 
MS; Mass Spectrometry 
NIR; Near-Infrared Spectroscopy  
NMR; Nuclear Magnetic Resonance Spectrometry  
QA; Quality assessment 
QC; Quality control 
RC: Resistance- Capacitance 
RSD: Relative Standard Deviation 
S.B.W. Spectral Band Width 
TLC; Thin Layer Chromatography 
USP: United State Pharmacopeia 
UV; Ultra Violet 
WHO; World Health Organization 
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1.1. Quality Assurance of pharmaceutical products 
Although medicinal products are subject to quality–control testing by the 
manufacturer, they may also have to be checked independently to: 
• determine or confirm their composition  
• assess their suitability for use  
• investigate defects  
• identify unknown medicinal products  
• identify contaminants  
• determine if the products have been adulterated  
• establish if the products are counterfeit.  
Independent quality checks of medicinal products may be carried out by official 
medicines control laboratories, as part of a government surveillance programme, 
and by hospital quality–control laboratories, public analyst laboratories and 
forensic laboratories 
A wide range of tests that utilize a variety of analytical techniques are available to 
pharmaceutical analytical laboratories. Samples submitted to an independent 
laboratory for testing, therefore, should be accompanied by a clear written request 
about the nature of the investigation required. The provision of relevant 
background information about the sample, including the reason for the request, 
allows the laboratory to choose the most appropriate tests, analytical techniques 
and, where relevant, acceptance criteria. 
In most cases that involve checking of the quality of a medicinal product, it is 
preferable to use the test methods in the product specification defined in the 
manufacturer’s marketing authorization for the product. This is because the 
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product specifications, including the test methods and acceptance criteria, have 
been assessed by the government regulatory agency as being valid and justified. 
Some manufacturers publish their analytical methods in the scientific literature. 
Consequently, it may be worthwhile to check the literature or maintain a library of 
published methods. Alternatively, in certain circumstances, manufacturers may 
provide the independent laboratory with the test methods, acceptance criteria and 
reference materials. 
If the laboratory does not have access to the authorized finished product 
specification, including the test methods and acceptance criteria, pharmacopoeial 
monographs can be used, where applicable. In the absence of a pharmacopoeial 
monograph, alternative approaches are required to obtain as much information as 
possible about the quality of the medicinal product. This requires the development 
of valid test methods to measure relevant quality parameters and the application of 
generally accepted criteria to assess the quality. However, if the laboratory uses 
different analytical techniques to those used by the manufacturer [e.g. a high 
performance liquid chromatographic (HPLC) technique instead of an ultraviolet 
(UV) spectrophotometric technique], the results may differ significantly from 
those obtained by the manufacturer, particularly if high levels of impurities are 
present. This is because analytical techniques differ in their accuracy, precision, 
selectivity and/or specificity and sensitivity. It is important, therefore, to consider 
the findings in relation to the technique used (Anthony et al, 2003). 
1.2. Pharmacopoeial specification and methods 
Pharmacopoeias are good sources of the specifications and standards with which a 
wide range of commonly used drug substances, excipient, packaging materials 
and finished products must comply throughout their shelf–life. The principal 
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pharmacopoeias are the European Pharmacopoeia (Council of Europe, 2002), 
British Pharmacopoeia (The Stationery Office, 2002); and the United States 
Pharmacopeia (US Pharmacopoeial Convention, 2002).  
National pharmacopoeias of some countries, for example Japan, China and 
individual European countries, may provide specifications for pharmaceuticals 
that are available only in those countries. The International Pharmacopoeia 
published by the World Health Organization is intended for use by WHO member 
states who wish to establish pharmacopoeial requirements for pharmaceuticals 
used in their country (World Health Organization, 1979, 1981, 1988, 1994 and 
2001). 
 Pharmacopoeial monographs for medicinal products provide good models upon 
which the testing of non–pharmacopoeial products should also be based when a 
general check of their quality is required. Typical pharmaceutical specifications 
for dosage forms include the following types of tests to provide assurance of their 
quality, safety and efficacy: 
• Identity test to confirm the identity of the active ingredient(s) and, if 
appropriate other important constituents (e.g. preservatives) 
• Assay of the active ingredient(s) and, if appropriate other constituents  
• Homogeneity (e.g. uniformity of content for tablets and capsules)  
• Release of the active ingredient from the formulation Drug–related impurities 
and other contaminants  
• Microbiological tests (e.g. sterility tests for injectable and ophthalmic products  
Pharmacopoeias contain useful chemical, physical and microbiological 
information about drug substances, excipient and dosage forms. Examples include 
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molecular structures and formulae, relative molecular masses, melting and boiling 
points, spectroscopic data and solubility in various solvents. 
If a test method is required for a pharmaceutical product for which there is no 
pharmacopoeial monograph, it may be possible to use or adapt the test methods in 
a monograph of a similar material. In these circumstances, however, relevant 
validation tests should be carried out, such as recovery, precision, robustness, 
selectivity and/or specificity and (for trace amounts, e.g. impurities) limits of 
detection and quantification, to provide confidence in the suitability of the adapted 
method. 
Pharmacopoeial monographs generally do not rely on a single analytical 
technique, but instead contain a number of tests based on different analytical 
methodologies (e.g. identity tests that use spectroscopic techniques and colour 
reactions, tests for impurities using chromatographic techniques and assays using 
a non–selective titrimetry or UV spectrophotometric technique). Pharmacopoeial 
authorities consider that this approach provides the optimum level of assurance 
about the quality of the product.  
1.3. Types of Quality testing  
1.3.1. Qualitative testing 
1.3.1.1. Physical defect 
The laboratory should undertake thorough visual examination for physical defects 
as part of the sample receipt procedure. If one or more physical defects are 
detected in a batch of medicinal product, the batch is usually withdrawn or 
recalled from the market, even if the visual defect does not directly affect the 
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safety and efficacy of the product. If visual defects are observed, appropriate tests 
should be carried out to investigate the cause.  
1.3.1.2. Basic tests of drug substances and products 
Some underdeveloped countries do not have access to fully equipped laboratories 
and the use of rapid, basic tests offers a cost–effective alternative approach to the 
detection of sub–standard medicines, including counterfeit products.  
The basic tests described which are designed to verify the identity of drug 
substances and medicinal products and to detect gross contamination, use a 
limited range of readily available reagents and equipment. 
Tests to verify identity are based on a combination of organoleptic checks, as 
described above for counterfeit products, and simple physicochemical tests, such 
as color reactions (‘test tube methods’) and melting–point determinations, (World 
Health Organization, 1986). 
Semi–quantitative TLC methods have been developed as basic tests using a 
limited number of solvent systems and detection systems, (World Health 
Organization, 1998).  
It should be emphasized that basic tests are intended not to replace pharmacopoeia 
requirements, but to provide a rapid, inexpensive means to verify identity and 
strength and possibly detect poor–quality counterfeit and other sub–standard 
products. When suspect products are detected, they should be tested for 
compliance with pharmacopoeial requirements. 
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1.3.2. Quantitative testing 
1.3.2.1. Content of active ingredients 
In a medicinal product content of active ingredients is one of the most important 
quality parameters that assure its efficacy. As with other tests in a specification, if 
the laboratory does not have access to the assay method in the marketing 
authorization or if there is no relevant pharmacopoeial monograph for the product, 
a suitable assay should be developed. It may also be necessary to quantify 
excipient that has a critical bearing on the safety or efficacy of the product (e.g. 
preservatives). 
1.4. Quality testing techniques 
Different techniques are used to identify the quality of pharmaceutical products. 
These include spectrophotometry (ultraviolet, visible and infrared), fluorimetry, 
atomic spectroscopy (absorption and emission), mass spectrometry, nuclear 
magnetic resonance spectrometry (NMR), X- ray spectroscopy (absorption, 
fluorescence), electroanalytical techniques (poteneiometry, voltametry and 
electrolysis), chromatography techniques (liquid and gas), gravimetry, titrimetry, 
and radiochemistry. Different techniques possess varying degrees of selectivity, 
sensitivity, precision, accuracy, cost and speed. 
The most common and widely used techniques are spectrophotometry and 
chromatography. 
• Spectrophotometry and light scattering 
Absorption spectrophotometry is the measurement of an interaction between 
electromagnetic radiation and the molecules, or atoms, of a chemical substance. 
Techniques frequently employed in pharmaceutical analysis include UV, visible, 
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IR, and atomic absorption spectroscopy. Spectrophotometric measurement in the 
visible region was formerly referred to as colorimetry. However, it is more precise 
to use the term "colorimetry" only when considering human perception of colour. 
Fluorescence Spectrophotometry is the measurement of the emission of light from 
a chemical substance while it is being exposed to UV, visible or other 
electromagnetic radiation. In general, the light emitted by a fluorescent solution is 
of maximum intensity at a wavelength longer than that of the exciting radiation, 
usually by some 20 to 30nm or more. 
Light – scattering involve measurement of the light scattered because of 
submicroscopic optical density in homogeneities of solutions and is useful in the 
determination of weight- average molecular weights of polydisperse systems in 
the molecular weight range from 1000 to several hundred million. Two such 
techniques utilized in pharmaceutical analysis are turbidimetry and nephelometry. 
Raman spectroscopy (inelastic light – scattering) is a light – scattering process in 
which the specimen under examination is irradiated with intense monochromatic 
light (usually laser light) and the light scattered from the specimen is analyzed for 
frequency shifts. 
The wavelength range available for these measurements extends from the short 
wavelengths of the UV through the IR. For convenience of reference, this spectral 
range is roughly divided into the UV (190 to 380nm), the visible (380 to 780nm), 
the near- IR (780 to 3000nm), and the IR (2.5 to 40 µm or 4000 to 250cm-1), 
(USP, 2007) 
For many pharmaceutical substances, measurements can be made in the UV and 
visible regions of the spectrum with greater accuracy and sensitivity than in the 
near- IR and IR. When solutions are observed in 1-cm cells, concentrations of 
about 10 µg of the specimen per ml often will produce absorbencies of 0.2 to 0.8 
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in the UV or the visible region. In the IR and near- IR, concentrations of 1 to 10 
mg per ml and up to 100 mg per ml, respectively, may be needed to produce 
sufficient absorption; for these spectral ranges, cell lengths of from 0.01mm to 
upwards of 3mm are commonly used. 
The UV and visible spectra of substances generally do not have a high degree of 
specificity. Nevertheless, they are highly suitable for quantitative assays, and for 
many substances they are useful as additional means of identification.           
There has been increasing interest in the use of near- IR spectroscopy in 
pharmaceutical analysis, especially for rapid identification of large numbers of 
samples, and also for water determination. 
The near IR region is especially suitable for the determination of – OH and – NH 
groups, such as water in alcohol, - OH in the presence of amines, alcohols in 
hydrocarbons, and primary and secondary amines in the presence of tertiary 
amines. 
The IR spectrum is unique for any given chemical compound with the exception 
of optical isomers, which have identical spectra. However, polymorphism may 
occasionally be responsible for a difference in IR spectrum of a given compound 
in the solid state. Frequently, small differences in structure result in significant 
differences in the spectra. Because of the large number of maxima in an IR 
absorption spectrum, it is sometimes possible to quantitatively measure the 
individual components of a mixture of known qualitative composition without 
prior separation. 
The Raman spectrum and the IR spectrum provide similar data, although the 
intensities of the spectra are governed by different molecular properties. Raman 
and IR spectroscopy exhibit different relative sensitivities for different functional 
groups, e.g., Raman spectroscopy is particularly sensitive to C-S and C-C multiple 
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bonds and some aromatic compounds are more easily identified by means of their 
Raman spectra. Water has a highly intense IR absorption spectrum, but a 
particularly weak Raman spectrum. Therefore, water has only limited IR 
"windows" that can be used to examine aqueous solutes, while its Raman 
spectrum is almost completely transparent and useful for solute identification. The 
two major limitations of Raman spectroscopy are that the minimum detectable 
concentration of specimen is typically 10-1 M to 10-2 M and that the impurities in 
many substances fluoresce and interfer with the detection of the Raman scattered 
signal.      
1.4.1. Ultraviolet- Visible spectrophotometry 
The technique involves the measurement of the amount of ultraviolet UV (190- 
380nm) or visible (380-800nm) radiation absorbed by a substance in solution. 
Absorption of light in both the UV and visible region of the electromagnetic 
spectrum occurs when the energy of the light matches the energy required to 
induce an electronic transition and it is associated with vibration and rotational 
transition in the molecule. 
Spectral selectivity can be induced and/ or enhanced by a number of chemicals or 
by instrumental technique such as difference, higher- derivative and dual 
wavelength spectrophotometry. 
Spectral interference can often arise from what is known as "irrelevant" 
nonspecific absorption, and also from absorption by other materials and 
impurities, which may be present. 
When interference is due to spectral overlap of two or more well- defined 
components, a number of methods can be adopted to measure the individual 
concentrations. These methods include the Vierordt multi wavelength technique, 
least squares deconvolution and second or higher derivative spectrophotometry. 
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1.4.1.1. Quantitative spectrophotometry assay of pharmaceutical    substance 
The assay of an absorbing substance may be carried out by making a solution of 
the substance in a transparent solvent and measuring its absorbance at a suitable 
wavelength. The wavelength normally selected is a wavelength of maximum 
absorption (λmax) where small errors in the settings of the wavelength scale will 
have little effects on the measured absorbance. 
Ideally, the concentration should be adjusted to give an absorbance reading of 
approximately 0.9, around which the accuracy and precision of measurement are 
optimal. It is often preferred to read the absorbance from the instrument display 
under non- scanning conditions, i.e. with the monochromator set at the analytical 
wavelength. Alternatively, the absorbance can be read from a recorded spectrum 
of the substance obtained by using a recording double- beam spectrophotometer. 
The later procedure is of particular usefulness for qualitative purposes and in 
certain assays in which absorbance at more than one wavelength is required. The 
concentration of the absorbing substance can be calculated from the measured 
absorbance using one of the three principal procedures. 
A.  Use of standard absorpativity value 
This procedure is adopted by official compendia, e.g. British Pharmacopoeia for 
stable substances 
B. Use of calibration graph 
 In this procedure the absorbancies of a number of standard solutions (4-6) of 
reference substance at concentrations encompassing the sample concentration are 
measured and a calibration graph is constructed. Concentration of analyte can then 
be read from graph. 
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C. Single and double point standardization 
The single point procedure involves the measurement of the absorbance of a 
sample solution and of a standard solution of the reference substance. The 
standard and sample solutions are prepared in a similar manner; final 
concentration of the sample solution should be close to that of the standard 
solution. 
The concentration of the substance in the sample can be calculated from 
proportional relationship that exist between absorbance and concentration  
Ctest = Atest X Cstd 
              Astd 
Where Ctest and Cstd are the concentrations of sample and standard solutions 
respectively, and Atest  and  Astd are the absorbances of sample and standard 
solutions respectively. 
1.4.1. 2. Assay of substance in multicomponent sample 
Pharmacopoeial applications include assays for single and mixtures of drugs 
analysis involving color reactions (colorimetric methods), test for tablet 
dissolution, limit test for impurities, and assays of bulk drugs. Further applications 
are for physicochemical measurements, such as pKa or velocity constants in 
enzymatic reactions.  
The scope of such applications has been significantly extended by methods, which 
can confer additional specificity, namely difference spectrophotometry, 
simultaneous equation method, absorbance ratio method, geometric correction 
method and orthogonal method. The spectrophotometric assay of drugs often 
involves the measurement of absorbance of samples containing more than one 
absorbing component. 
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A number of modifications to the simple spectrophotometric procedure have been 
introduced, which may eliminate certain sources of interference and permit the 
accurate determination of one or all of the absorbing components. 
Each modification of the basic procedure may be applied if certain criteria are 
fulfilled. The basis of the spectrophotometric techniques for multi- component 
analysis of samples is the property that at all wavelengths: 
a. The absorbance of solution is the sum of the absorbencies of the individual 
components. 
b. The measured absorbance is the difference between the total absorbance of 
the solution in the sample cell and that solution in the reference cell (blank). 
1.4.1.2.1. Assay of single components  
When only one component in the sample absorbs significantly, the wavelength is 
chosen to coincide with the centre of a broad maximum in the spectrum in order 
to minimize errors due to wavelength – setting. In cases where the spectrum has 
no suitable maximum, a flat absorption minimum can be used, provided that the 
expected consequent loss of sensitivity is acceptable. Wavelengths near the limits 
of the ultraviolet and visible ranges must be avoided, because of the possibilities 
of stray – light errors. 
The concentration of a component in a sample, which in addition contains other 
absorbing substances, may be determined by a simple Spectrophotometric 
measurement. This is possible only if the other components have a small 
absorbance at the wavelength of measurement. This condition will be met if the 
concentration of the interfering substances, their absorbtivity or the path length of 
the solution is sufficiently small that their product can be ignored. An example of 
this method is the assay of paracetamol in paediatric paracetamol elixir. 
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1.4.1. 2.2. Assay –using absorbance corrected for interference 
If the nature, concentration and absorptivity of the absorbing interferents are 
known, it will be possible to calculate their contribution to the total absorbance of 
a mixture. The concentration of the absorbing component of interest can then be 
calculated from the corrected absorbance (total absorbance minus the absorbance 
of interfering substances). 
1.4.1.2. 3. Assay after solvent extraction of the sample 
If interference resulting from other absorbing substances is very large or if its 
contribution to the total absorbance cannot be calculated, it may be required if 
possible to separate the absorbing interferents from the analyte by solvent 
extraction procedures. These procedures are appropriate especially for acidic or 
basic drugs where the state of ionization determines their solvent partitioning 
behaviour. Such an example is the assay of caffeine in aspirin and caffeine tablets 
(B.P.). 
1.4.1.2. 4. Simultaneous equation method 
If a sample contains two absorbing drugs each of which absorbs at λmax of the 
other, it may be possible to determine both drugs by applying the technique of 
simultaneous equations (Vireodt's method) provided that certain criteria are 
fulfilled. An example of such assay is described in the B.P. for the assay of 
quinine related alkaloids and for cinchona- related alkaloids in Cinchona Bark. 
(Donbrow, 1967) 
1.4.1.2.5. Absorbance ratio method 
The absorbance ratio’s method is a modification of the simultaneous equation 
procedure. It depends on the property that, for a substance, which obeys Beers 
Law at all wavelengths, the ratio of absorbance at any two wavelengths is a 
constant value independent of concentration or path length. In the quantitative 
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assay of two components in admixture by the absorbance ratio method, 
measurement of absorbance are made at two wavelengths one being the λmax of 
one of the two components (λ2) and the other one being a wavelength of equal 
absorbtivity of the two components (λ1), i.e., an iso- absorptive point (Pernarowski 
et al, 1960). 
 This method is applied for the assay of trimethoprim and sulphmethoxazole in 
co- trimoxazole; (Ghanem, et al, 1979). 
1.4.1.2.6. Geometric correction method 
Mathematical correction procedures have been developed to reduce or eliminate 
the background irrelevant absorption that may be present in samples of biological 
nature. The simplest of these procedures is the three – point geometric procedure, 
which is applicable if the irrelevant absorption is linear at the three wavelength 
selected. The assay of vitamin A in fish liver oils furnishes an example for the 
geometric correction method. 
1.3.1.2.7. Orthogonal polynomial method 
The technique of orthogonal polynomials is another mathematical correction 
procedure, which involves more complex calculations than the three – point 
correction procedure; (Glenn, 1963) 
The basis of the method is that an absorption spectrum may be represented in 
terms of orthogonal function as follows: 
A (λ) = p0P0(λ) + p1P1(λ) + p2P2(λ).........pnPn(λ) 
Where A is for the absorbance at wavelength λ belonging to a set of n + 1 equally 
spaced wavelengths at which the orthogonal polynomials p0P0(λ), p1P1(λ),  
p2P2(λ).........pnPn(λ) are each defined. 
This method is applied in the selective assay of phenobarbitone, combined with 
phenytoin in a capsule formulation; (Amer et al, 1977). 
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1.4.1.2.8. Difference spectrophotometry 
Both selectivity and accuracy of spectrophotometric analysis of samples, which 
contain absorbing interferons, may be greatly improved by the technique of 
difference spectrophotometry. In difference spectrophotometric assays the 
measured value is the difference in absorbance (∆A) between two equimolar 
solutions of the analyte, in different chemical forms, which exhibit difference 
spectral characteristics. 
Difference spectrophotometry is a technique of compensating for the extraneous 
materials present in a sample, which might interfere with the spectrum of the drug 
being determined. It involves the measurement of difference in the absorbance, at 
a defined wavelength, between two samples in one of which a physical or 
chemical property of the drug has been changed. It is assumed that the spectrum 
of the drug can be changed without affecting the spectrum of the interfering 
material. Alternatively, the absorbance difference between the sample and an 
equivalent solution without the drug may be measured. Difference 
spectrophotometry is sometimes referred to as 'differential spectrophotometry, but 
this is not recommended since it might be confused with derivative 
spectrophotometry. 
Certain criteria are required for applying difference spectrophotometry for the 
analysis of a substance in the presence of other absorbing substances: 
1. Reproducible changes are induced in the spectrum of the analyte by the 
addition of one or more reagents. 
2. The absorbance of the interfering substances is not altered by the addition 
of such reagents. 
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The simplest and most commonly used technique for altering the spectral 
properties of the analyte is the adjustment of the pH of the solution by means of 
aqueous solution of acids, alkalis or buffers. 
On the other hand a substance whose spectrum is not affected by changes in pH 
may also be determined by a difference spectrophotometric procedure. 
This can be done by quantitatively converting it, using a suitable reagent, to a 
chemical species that has different spectral properties from the untreated parent 
substance. The ∆A between equimolar solutions of the untreated substance and 
the corresponding derivative is free of interference if the irrelevant absorption is 
unaffected by the reagent (Davidson, A. G. 1976). 
If :      ∆A =∆Є bc 
Where: 
 Є = molar absorptive (liter/mole/cm), 
   b = cell path- length (cm), 
   c = concentration (mol/liter). 
Then the difference absorbance can be related to concentration by the relation: 
∆Atest/∆Astandard  = Ctest/Cstandard 
It should, however, be established that ∆A is a linear function of concentration C. 
Difference spectrophotometry can be used for quality control if the interfering 
material is well- defined. In such a case an appropriate dilution of a suitable 
reference solution can be used in the reference cell. The technique of difference 
absorbance is subject to systematic error when there is uncertainty about the 
concentration of interfering materials in the samples to be assayed; 
This error increases in proportion to the ratio of the molar absorptivity of the 
interfering substance to that of the analyzed drug. 
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A further technique to correct for absorptive interferences by difference 
measurement is based on dual – wavelength spectrophotometry. In this method, 
two monochromatic beams at different wavelengths are passed through the same 
sample. One wavelength (λ1) is generally characteristic of the drug, while the 
other (λ2) is carefully selected so that the absorbance is equivalent to the level of 
absorptive interference (Aλ1m) anticipated at the analytical wavelength (λ1). The 
second radiation beam will thus be analogous to the reference cell employed in 
conventional difference Spectrophotometry. 
The difference in absorbance at the two wavelengths (∆A) represent the absorption 
of drug (Aλ1n) corrected for interference 
Aλ1 =  Aλ1n + Aλ1m 
And since  
Aλ2  = Aλ1m 
Then          ∆A = Aλ1 - Aλ2 = Aλ1n 
An application of this method is represented by the correction of Raleigh scatter 
in samples of biological origin. An example of this method is the selective assay 
of chlordiazepoxide and it is major hydrolysis product, demoxepam, in degraded 
formulation of chlordiazepoxide;( Davidson, 1984) 
1.4.1.2.9. Colorimetric measurement 
In colorimetric methods we can selectively transform a drug, its impurity, or its 
metabolite into a derivative so that spectrum of the derivative is shifted to the 
visible region. 
This will minimize interference caused by another drug, formulation components 
or biological substances, thereby conferring a further degree of specificity. 
Moreover, a drug with little or no useful absorption can be more highly- 
absorptive chromophore. 
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There are several parameters, which require careful and critical consideration in 
colorimetry. Firstly, the colour reagent should be selective for the drug molecule 
itself, discriminating degradation products, impurities, and formulation excipient 
which might be present. Secondly, the effect and control of any parameters, which 
is likely to affect the colour reaction or stability  should be established, i.e. 
solvent, pH, temperature, reagent excess, order of mixing reagents, and other 
related factors.  
Moreover, the time required to establish the chromophore generated, should be 
carefully monitored and assessed. Finally, the analytical performance should be 
assessed in terms of recovery, precision, sensitivity, linear range, and robust 
behaviour. 
1.3.1.2.10. Derivative spectrophotometry 
In derivative spectrophotometry the absorbance (A) of a sample is differentiated 
with respect to wavelength (λ) to generate the first, second, or higher order 
derivative, (Anthony et al, 2006). 
 In the context of derivative spectrophotometry, the normal absorption spectrum is 
referred to as the fundamental, zero order or 0D spectrum. 
A = f (λ)   dA/dλ = f' (λ)   d2 A/λ2 = f"  (λ) , etc. 
Zero order   first derivative   second derivatives 
The first derivative (1D) spectrum is a plot of the rate of change of absorbance 
with wavelength against wavelength, i.e. a plot of the slope of the fundamental 
spectrum against wavelength or a plot of  
dA/ dλ vs. λ. 
The second derivative (2D) spectrum is a plot of the curvature of the 0D spectrum 
against wavelength or a plot of d2 A/λ2 vs.λ  
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Spectra are seen as distinctive bipolar feature; the even order derivatives are 
bipolar functions of alternating sign at the centroid, whose position coincides with 
that of the original peak maximum. 
The first order derivative spectrum of an absorption band is characterized by a 
maximum, a minimum, and a crossover point at the λmax of the absorption band. 
The second derivative spectrum is characterized by two satellite maxima and an 
inverted band of which the minimum corresponds to the λmax of the fundamental 
band. 
A derivative spectrum therefore gives better resolution of overlapping bands than 
the corresponding fundamental spectrum and may permit the accurate 
determination of the λmax of the individual bands. Secondly, derivative 
spectrophotometry discriminates in favour of substances of narrow spectral band 
width against those with broad bandwidth. The derivative amplitude (D), i.e. the 
distance from a maximum to a minimum, is inversely proportional to the 
fundamental spectral band width (W) raised to the power (n) of the derivative 
order. Thus,  
D α (1/W)n 
And consequently, substances with narrow spectral bandwidth display larger 
derivative amplitudes than those with broad bandwidth (Beckett and Stenlake, 
2004). 
These advantages of enhanced resolution and band width discrimination found in 
derivative spectrophotometry permit the selective determination of certain 
absorbing substances in samples in which non-specific interference may limit the 
application of simple spectrophotometric methods. Ephedrine hydrochloride in 
ephedrine hydrochloride elixir is assayed by second derivative spectrophotometry, 
which eliminates the broad band absorption of the excipient. 
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The enhanced resolution and bandwidth discrimination increases with increasing 
order of derivative spectrophotometry. However, it should be noted that the 
concomitant increase in electronic noise inherent in the generation of the higher 
order spectra, and the consequent reduction of the signal- to – noise ratio, would 
confer practical limitations on the higher order spectra  
An important property of the derivative process is that broad bands are suppressed 
relative to sharp bands. This effect increases with increasing order of the 
derivative. This property leads to selective rejection of broad, additive, spectral 
interferences such as Rayleigh scattering. Davidson, A. G. and Hassan, S.M., 
1984(31) 
The factors which affect derivative measurements can be summarized as  
• The type of sample i.e. having sharp or broad spectral feature, requiring 
narrow or wide spectral band width (S.B. W.) respectively 
• The sample concentration, which will determine the absorbance level, and 
therefore produce high or low noise resolution 
• The wavelength region in which the sample absorbs, again producing either 
high or low noise condition  
• The selectable instrument operating parameters which will determine the 
quality of derivative data are;  
1. The scanning speed which will determine the sampling interval ∆λ for 
derivative calculation,  
2. The S.B.W. which will determine the resolution and the level of noise 
3. The smoothing filter times; which will determine the number of collected data 
points 
Derivative spectra can be obtained by any of three techniques. The earliest 
derivative spectra were obtained by modification of the optical system. 
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Spectrophotometers with dual monochromators set a small wavelength interval 
(∆λ, about 1-3nm) apart or with the facility to oscillate the wavelength over a 
small range, are required. In either case the photo detector generates a signal, 
which has amplitude proportional to the slope of the spectrum over the 
wavelength interval. 
The second technique employed to generate derivative spectra comprise electronic 
differentiation of the spectrophotometer analogue signal. Resistance- Capacitance 
(RC) modules may be incorporated in the series between spectrophotometer and 
recorder to provide differentiation of the absorbance, with respect to time and not 
wavelength, thereby producing the signal dλ/dt. 
If the wavelength scan rate is constant (dλ/dt = C), the derivative with respect to 
wavelength will be given by: 
dA/dλ = (dA/dt)( dλ/dt) = (dA/dt)( C) 
Where: 
dA/dλ = Change of absorbance with respect to wavelength. 
dA/dt = Change of absorbance with respect to time. 
dλ/dt = Change of wavelength with respect to time. 
C = Concentration (mol/litre). 
Derivative spectra obtained with RC modules are highly dependent on 
instrumental parameters, such as the scan speed and the time constant. It is 
important therefore to use a standard solution of the analyte to calibrate the 
measured value under the instrumental conditions selected. The third technique is 
based upon microcomputer differentiation; microcomputers incorporated into or 
interfaced with the spectra during or after the scan of the spectrum of the sample. 
For quantitative purposes, the amplitude of a derivative peak can be measured in a 
number of ways including peak- to – peak, peak- to- satellite at short wavelength, 
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peak- to- derivative zero, and peak- to- satellite at long wavelength and satellite 
peak- to- derivative zero. 
If Beer- Lamber law is obeyed,  
i.e.     A = εbc 
Then 
dA/dλ = dε/dλ . b.c 
d2 A/dλ2 = d2 ε/dλ2 . b.c 
And so on for a higher derivatives. 
Derivative spectrophotometry has found significant application in clinical, 
forensic, and biomedical analysis. 
Derivative spectroscopy has been widely applied in the analysis of different 
pharmaceutical dosage forms. It solves the problem of analysis associated with 
drugs combination, stability studies of drug and degradation products, drug 
impurities, interference of excipient in drugs, topical preparations analysis like 
creams and ointments. It also solves the problem of analysis of drugs in biological 
fluids and is also used in clinical –pharmaceutical-biochemical (life sciences) 
A number of reports have been cited for the application of derivative methods for 
solving analytical problems. Example of these are the analysis done by Nevin, 
2001for binary mixtures of losartan potassium and hydrochlorothiazide, the assay 
of ephedrine hydrochloride and theopylline in pharmaceutical formulations Nevin, 
2000, the quantitative analysis of chloropheniramine maleate and phenylephrine 
hydrochloride in nasal drops Nevin, 2000 and the determination of 
hydrochlorothiazide and benzapril hydrochloride using 2nd derivative reported 
(Panderi, 1999). Second derivative spectrophotometry method has been applied for 
the simultaneous determination of vitamin C and dipyrone Aburajai etal, 2000. It 
has been reported the application of derivative spectrophotometry for the 
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determination of enoxacin and nalidixic acid in tablets, Hopkala and Kowalczuk, 
2000. Other work reported is the determination of amlodipine- enalapril maleate 
and amlodipine- lisinopril in tablets, simultaneous determination of tinidazole, 
furazolidone and diloxanide furoate in a combined tablet preparation by second-
derivative spectrophotometery Prasad et al, 1999 and the work done by Vega and 
Sola, 2001for quantitative analysis of metronidazole in intravenous admixture with 
ciprofloxacin by first derivative spectrophotometry. 
The application of derivative spectroscopy as stability indicating method for the 
study of degradation and decomposition of drugs during stability studies has been 
reported by El- Gindy et al, 2001for the determination of acebutolol HCl in 
presence of it is acid induced degradation products. El- Gindy, 2000 reported the 
determination of benoxinate hydrochloride and its degradation product by first 
derivative spectrophotometry.   
El Walily et al, 1999 reported the simultaneous determination of tenoxicam and it 
is decomposing product using derivative spectrophotometry and HPLC. 
Derivative methods have been applied in the determination of drugs in other 
pharmaceutical dosage form such as creams and ointments, as reported by Wrobel 
et al, 999 in the application of derivative spectrophotometry in the determination of 
miconazole in pharmaceutical creams. Analysis of miconazole and econazole in 
pharmaceutical formulations by derivative UV spectroscopy and liquid 
chromatography (HPLC) was reported by Cavrini, et al, 1989. 
Derivative methods have been reported for the analysis of drugs in biological 
fluids, as in the report by El- Gindy et al, 2000 the determination of cefuroxime and 
cefadroxil in urine. 
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1.4.2. Chromatographic techniques 
Chromatography was first discovered and named in 1906 by (Michael) there are 
many types of chromatography. Size exclusion chromatography is the one in 
which molecules are separated based on their size by passage through a porous 
structure stationary phase. In ion exchange and ion chromatography, ions are 
separated based on their charge. In gas chromatography, gaseous substances are 
separated according to their adsorption on or solubility in the stationary phase; 
high performance liquid chromatography is a modern technique based on the 
above principles but using micrometer size particles for the stationary phase. 
Other type of chromatography include thin- layer chromatography, paper 
chromatography, and electrophoresis in which the stationary phase is in the form 
of a sheet or other flat surface and an electrical gradient is applied across the sheet 
to cause molecules to migrate according to the sign and magnitude of their charge. 
All chromatographic techniques are principally based on establishment of 
equilibrium between a stationary phase and a mobile phase. The mechanism of 
retention however differs for various type of chromatography  
Chromatography is essentially a group of techniques for the separation of the 
compounds of mixtures by their continuous distribution between two phases, one 
of which is moving past the other. The systems associated with this definition are: 
1. A solid stationary phase and a liquid or gaseous mobile phase (adsorption 
chromatography) 
2. A liquid stationary phase and a liquid or gaseous mobile phase (partition 
chromatography) 
3. A solid polymeric stationary phase containing replaceable ions and an ionic 
liquid mobile phase (ion exchange chromatography) 
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4. An inert gel which acts as a molecular sieve, and a liquid mobile phase (gel 
chromatography). 
The basis of the separation of the components of a mixture may be defined in 
terms of one of these four modes of separation, or by a combination. 
1.4.2.1. High performance liquid chromatography 
The technique of high performance liquid chromatography (HPLC) was 
developed in the late 1960s and early 1970s from knowledge of the theoretical 
principles that already had been established for the early chromatographic 
techniques in particular for column chromatography, and from advances made in 
column packing materials and in the design of chromatographic equipment. HPLC 
is a relatively modern analytical technique and it is preferred for the rapid 
separation of non- volatile or thermally unstable samples; the technique is based 
on the same mode of separation as classical column chromatography i.e. 
adsorption, partition (including reversed –phase partition), ion exchange and gel 
permeation, but it differs from column chromatography in that the mobile phase is 
pumped through the packed column under high pressure. The difference between 
the classical liquid chromatography (LC) and HPLC is that for classical LC large 
porous particles are packed into columns while in HPLC columns are packed with 
pellicular or micro particulate packaging particles. 
An increase in column efficiency with decreased porous particles results from 
development of pellicular packing and micro particulate which lead to use of short 
columns with smaller internal diameter. 
The principal advantages of HPLC compared to classical column chromatography 
are improved resolution of the separated substances, faster separation times and 
the increased accuracy, precision and sensitivity with which separated substance 
may be quantified. 
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HPLC is the most widely used technique in pharmaceutical analysis; this due to 
• The wide variety of packing material allow separation of most compound 
• The different type of detectors available permit the sensitivity detection of 
most chemical types 
• Microparticulate  packing materials give excellent separation of similar 
substance; martin and  
• The short column (3-10 cm) in routine use allow fast separation and 
complete separation of a complex mixture can be achieved within a few 
minutes 
• The use of automatic samplers and injectors enables large number to be 
analyzed in short time 
1.5. Validation of analytical methods 
Analytical methods should be characterized and documented fully, and their 
reliability in the specified area of application demonstrated before they are 
brought into use. Such method–validation ensures that methods are under 
statistical control and are fit for their intended purpose. Validation should cover 
all stages through sample selection and preparation, analyte recovery, calibration 
of equipment, the analysis protocol and the assessment, interpretation and 
reporting of results. 
Validation of methods for the quantitative analysis of drugs involves determining 
as a minimum, their selectivity, and limit of detection, limit of quantification, 
linearity, working range, accuracy, precision and ruggedness under the conditions 
and with the typical sample matrices that will be met in practice. For qualitative 
analysis, usually only the selectivity, limit of detection and ruggedness are 
important. Where there is a predefined threshold concentration for reported 
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results, the accuracy and precision should be determined at the threshold level. 
For methods that are to be used by more than one laboratory, each laboratory 
should verify the method, and the inter laboratory variation should be determined. 
These data should be used to define how the performance of the method is to be 
monitored through QC and to specify what performance is fit for purpose. If it is 
necessary to compare the results with those from other methods, the compatibility 
of data from the different methods should also form part of the validation. 
Any subsequent change at any stage of the method, or in the sample matrix or 
concentration range, will require revalidation of the method. The extent and 
requirements of revalidation will depend on what changes have been made. 
Where a laboratory adopts an already validated method, it should demonstrate that 
the performance characteristics it can achieve are fit for the intended purpose of 
the method. Particularly important in this respect are selectivity (if the sample 
matrix is different), limit of detection, accuracy and precision. 
In addition to analytical validation, it may also be necessary to carry out clinical 
validation. This requires: 
• Determination of expected concentrations  
• Differences associated with age, sex or other factors  
• Cut–off values to classify results as ‘normal’ or ‘abnormal’, or as decision points 
in screening  
• Clinical sensitivity (‘positivity in users’)  
• Clinical specificity (‘negativity in non–users’);  (Anthony et al., 2003) 
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1.5.1. Limit of detection 
The limit of detection is the lowest content of analyte that can be distinguished 
from background noise and measured with reasonable statistical certainty. It is 
estimated from the analysis of blank specimens and a study of the signal–to–noise 
ratio, with a minimum ratio of 3:1 being widely accepted.  
It is calculated by the equation;            
 x - xB=3sB 
Where x is the signal from the sample, xB is the signal from the analytical blank 
and sB is the SD of the reading for the analytical blank; (Miller and Miller, 1993) 
1.5.2. Limit of quantification 
The lower limit of quantification is the amount equal to or greater than the lowest 
concentration point on the calibration curve that can be measured with an 
acceptable level of accuracy and precision. 
1.5.3. Linearity 
Linearity is a measure of the ability of the method to elicit test results that are 
directly or, by means of well–defined mathematical transformations, proportional 
to the concentration of analyte within samples within a given range. 
1.5.4. Precision 
Precision is the closeness of agreement between independent test results obtained 
under prescribed conditions. It depends on analyte concentration and the 
distribution of random errors, and is often measured under repeatable (same 
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analyst, same day, same instrument, same materials) and reproducible conditions. 
Normally, it is expressed in terms of the coefficient of variation (CV) or relative 
standard deviation (SD) of the test results. An acceptable CV of 20% at the lowest 
calibration point and 15% for higher concentrations is usually acceptable. The 
acceptance criteria may be widened in circumstances in which matrix effects may 
be significant (e.g. analysis of autopsy samples), or tightened where better 
reliability is required.  
1.5.5. Method comparison 
The comparison of two methods should be carried out using a suitable statistical 
procedure to test if there are significant differences between them. The t–test 
provides a simple check on accuracy and the F-test on precision. The data sets 
should also be compared by orthogonal or robust (e.g. Deming) regression 
analysis for proportional and constant deviations. A minimum of 20 data points is 
recommended for these purposes. 
1.6. Drugs selected for the study 
The purpose of the present work is to develop derivative spectrophotometry 
methods for analysis of some pharmaceutical preparations; the selection of these 
preparations based on their widely used, they are chemically related, there are 
different brands available in the market and the official methods for their analysis 
either HPLC or titration. 
1.6.1. Drugs for helminthes treatment 
There are many drugs used for treatment of helminth infection of which are; 
niclosamide, mebendazole, praziquantel, albendazole, thiabendazole and 
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levamisole . We choice albendazole and mebendazole for our study as they widely 
used  
1.6.1.1. Albendazole 
Chemical structure;  
   
                         C12H15N3O2S=265.3  
 [5-(Propylthio)-1H-benzimidazol–2–yl]carbamic acid methyl ester  
Colorless crystals,  M.p. 208° to 210°. 
A white or faintly yellowish powder, practically insoluble in water, freely soluble 
in anhydrous formic acid, very slightly soluble in methylene chloride, practically 
insoluble in alcohol. 
Literature survey reveals several methods for analysis of albendazole including 
HPLC with florescence detector reported by (Lanchote, 1998).  Another HPLC 
method with UV detection reported by (Valois, 1994).  
The official method for analysis of albendazole tablet and suspension is by an 
HPLC (USP) method and bulk powder by non aqueous titration. Several works 
have been reported for quantification of albendazole and metabolites in biological 
fluids (Chiap, 2000). Other works done by Zeugin, (1990), for determination of 
albendazole and it is metabolites in plasma using UV detector 
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1.6.1.2. Mebendazole 
Chemical structure: 
 
                C16H13N3O3=2953 
Methyl-(5–benzoyl–1H-benzimidazol–2–yl) carbamate  
A white to slightly yellow amorphous powder; M.p. about 290°C practically 
insoluble in water, ethanol, chloroform, ether and dilute mineral acids; soluble in 
formic acid  
The official method for analysis of mebendazole tablet is an HPLC method and 
for suspension is UV method after prior extraction whiles the analysis of bulk 
powder is done by non aqueous titrations.  
Literature survey reveals the analysis of mebendazole in biological fluid. The 
detection of mebendazole and it is metabolite in plasma by HPLC using UV 
detection was reported by (Allan, 1980). 
In serum mebendazole and it is metabolite is detected by colorimetric was 
reported by (Betto, 1991). 
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1.6.2. Antiprotozoal drugs 
Many drugs such as metronidazole, sodium stibogluconate, benznidazole, 
pyrimethamine/sulphasalazine, sulphamethoxazole/ trimethoprim, etc are used as 
antiprotozoal agents 
The drugs selected for the present study are: 
1.6.2.1. Metronidazole 
Chemical structures; 
 
                C6H9N3O3=171.2 
2-Methyl–5–nitroimidazole–1–ethanol 
A white to pale yellow crystalline powder or crystals; it darkens on exposure to 
light. M.p. 158° to 160° 
Soluble 1 in 100 of water, 1 in 200 of ethanol, and 1 in 250 of chloroform; soluble 
in dilute acids; slightly soluble in ether.  
There are several methods for quantification of metronidazole in dosage form, in 
bulk powder and in biological fluid. HPLC analysis was done by Kaye, (1980), 
for analysis of metronidazole and it's metabolites in plasma, serum, saliva, whole 
blood and urine using UV detection. Another method for the detection of 
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metronidazole and it is metabolites in plasma by an HPLC using UV detection 
was described by (Gibson R. A., 1984).  Metronidazole and chloroquine were 
detected in plasma and urine using UV detection in a method reported by, 
(Okonkwo and Eta, 1988). The drug was determined in vaginal tissue in a report 
by (Venkateshwaran and Stewart , 1995). It was also detected in plasma, saliva, or 
gastric juice together with its hydroxy metabolite by HPLC method described by, 
(Jessa, 1996).  
Metronidazole is used in combination with different drugs as treatment therapy. 
Literature survey revealed several methods for analysis of these combinations in 
biological fluids. Metronidazole and omeprazole in gastric fluid and plasma were 
analyzed by the HPLC method reported by (Yeung, 1998). The detection of 
amoxicillin and metronidazole in plasma by HPLC method using photodiode 
array detector was reported by (Menelaou, 1999). 
The United State Pharmacopoeial (USP) method for analysis of metronidazole in 
dosage forms is an HPLC with UV detector and in pure forms is non aqueous 
titration. 
 The British Pharmacopeia (BP) method for it is analysis is non aqueous titration 
for bulk drug powder, suppositories and tablet dosage forms with prior extraction. 
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1.6.2.2. Metronidazole benzoate 
Chemical structure 
        
 
                             C13H13N3O4    275.3 
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate. 
Melting point 99 °C to 102 °C.  
White or slightly yellowish, crystalline powder or flakes.  
Practically insoluble in water, freely soluble in methylene chloride, soluble in 
acetone, slightly soluble in alcohol. 
The British Pharmacopeia method for it is analysis is non aqueous titration for 
pure drug substance and HPLC method with UV detection for oral suspension.  
1.6.2.3. Tinidazole 
Chemical structure;                        
 
                   C8H13N3O4S=247.3  
1-[2-(Ethylsulfonyl)ethyl]-2–methyl–5–nitro–1H-imidazole 
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Colourless crystals. M.p. 127° to 128° 
Practically insoluble in water, soluble in acetone and sparingly soluble in 
methanol. 
In the British Pharmacopeia the analysis of bulk powder is done by non aqueous 
titration. There are several methods for the detection of tinidazole in biological 
fluid, of which gas chromatography analysis using flame ionization detector (FID) 
was reported by Laufen, (1979) for analysis of tinidazole in plasma or tissues.  
HPLC method for detection of tinidazole in serum and urine was done by 
(Nilsson, 1981) it was also detected in serum by HPLC method using UV/Vis 
detector described by (Rajnarayana, 2002). 
1.6.3. Diuretics drugs 
1.6.3.1. Hydrochlorothiazide 
Chemical structure;                       
C7H8ClN3O4S2=2
97.7 
6-Chloro–3,4–dihydro–2H-1,2,4–benzothiadiazine–7–sulfonamide1,1–dioxide  
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It is a white crystalline powder. M.p. 273° to 275°, practically insoluble in water, 
chloroform, and ether; soluble 1 in 200 of ethanol and 1 in 20 of acetone; freely 
soluble in dimethylformamide and solutions of alkali hydroxides. 
The official BP method of analysis of hydrochlorothiazide is carried out in bulk 
by titration and in tablet dosage form by UV spectroscopy. Several methods have 
been reported for analysis of the drug in biological fluid, Redalieu et al. (1978), 
reported the detection of hydrochlorothiazide in plasma and blood by gas 
chromatography. A GC method for analysis of hydrochlorothiazide in plasma, 
erythrocytes or urine was described by Lindström et al., (1975) using ECD and 
FID detectors. Carreras et al., (1994), developed a method for analysis of 
hydrochlorothiazide in urine with other diuretics using gas chromatography–mass 
spectrometry.  
Hydrochlorothiazide and chlorothiazide were detected in plasma and urine by an 
HPLC with UV detection Barbahiya et al., (1981) and in plasma Kuo et al., 
(1990). Other reports on analysis of hydrochlorothiazide in plasma and urine 
using HPLC with UV-detector were published by Vries and Voss, (1993). 
Hydrochlorothiazide was analyzed in serum by an HPLC method using 
electrochemical detector Richter et al, (1996).  
1.5.3. 2. Amiloride Hydrochloride  
Chemical structure;   C6H8ClN7O, HCl, 2H2O=302.1          
 
3, 5-Diamino-N-(aminoiminomethyl)-6–chloropyrazinecarboxamide  
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A pale yellow to greenish–yellow powder; M.p. 285° to 288°, with 
decomposition; soluble in water and ethyl acetate, soluble 1 in 350 of ethanol, 
practically insoluble in chloroform and ether. 
The official BP and USP methods for quantification of amiloride hydrochloride in 
bulk powder is titration, while in pharmaceutical dosage forms, the USP method is 
an HPLC and the BP method is spectrophotometric method after extraction.  
There are many works reported for its quantification in biological fluids. The 
detection of amiloride hydrochloride in plasma, serum and urine by 
spectrofluorimetry was reported by Baer et al., (1967).    
A thin–layer chromatographic method has been developed by Reuter et al., 
(1982), for quantification of amiloride hydrochloride in plasma 
Literature survey revealed several methods for detection of amiloride 
hydrochloride in biological fluid. Amiloride HCl was analyzed in plasma by 
HPLC with fluorescence detector Reeuwijk et al., (1992). The detection of 
Amiloride hydrochloride in plasma and urine by HPLC with fluorescence 
detection was also described by Dan-Ke Xu et al., (1991). Park et al., (1990), 
reported an HPLC method with diode-array detector for the detection of the drug 
in urine. 
 
 
1.7. Objectives: 
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The assurance of pharmaceutical products as pure, stable, effective and safe is the 
role of government and also the information that permit optimum use of these 
products. It is important in many spheres to have reliable, interchangeable data on 
the recovery, identification and quantification of drugs. Acceptable limits for 
impurities that assure the drug’s safety depend on the toxicity of the impurity. The 
quality of a product may deviate from the standard required so carrying out 
analysis is important in order to determine the quality. 
Testing a pharmaceutical product involves chemical, physical, and sometimes 
microbiological evaluation or test; the procedure of testing vary from simple 
procedure to complicated one depending on the substance; in routine analysis we 
need simple, fast, cheap and accurate procedure. 
The UV-Visible spectrophotometric technique is rapid and simple, but has not 
been useful for the characterization of substances, even when pure. The relatively 
non-specifity has hindered it is wide application to qualitative analysis. 
The aims of the present work are 
1. Development and optimization of a derivative spectrophotometric method 
for analysis of mebendazole, tinidazole, albendazole metronidazole, 
metronidazole benzoate, hydrochlorothiazide and amiloride hydrochloride. 
2. Assessment of the selectivity, sensitivity, accuracy, repeatability and 
precision of the developed method 
3. Employing the developed method in the analysis of pharmaceutical dosage 
form  
4. comparison between the developed method and the official method for 
these products 
5. Asses the selectivity of method by analyzed different brand products and 
different dosage forms. 
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6. Carrying validation to the proposed methods 
7. Brought new possibilities for the universally used and frequently abused 
UV-Visible technique 
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Chapter Two 
 
Materials and Methods 
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2.1. Equipment  
2.1.1. Shimadzu spectrophotometer 
Model 1700-UV/ visible spectroscopy double beam with PC control and 
capability of derivative mode (Japan) 
2.1.2.  High performance liquid chromatography 
Shimadzu liquid chromatography, with UV/visible and diode ray- detector, 
isocratic and low pressure gradient pump and PC control (Japan) 
2.2. Chemicals and standard 
2.2.1. Chemicals 
The following chemicals were used; 
• Methanol HPLC grade, Scharlau; Spain 
• Methanol analytical grade, Scharlau; Spain 
• Hydrochloric acid PRS , Barcelona; Spain 
• Dimethylformamide , Central Drug House (CDH); India 
• Ammonium acetate , Labochemie; India 
•  Acetic acid , Riedel-Deaden; Germany  
• Ammonia , BDH Laboratory ; England 
• Monobasic sodium phosphate , BDH Laboratory; England 
• Monobasic potassium phosphate , Barcelona; Spain 
• Phosphoric acid BDH Laboratory; England  
• Sodium hydroxide PRS , Barcelona; Spain 
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2.2.2.  Standards 
The following working standards were used: 
• Mebendazole working standard, General Medicine Company, Khartoum 
Sudan; manufacture date May/2003, expiry date May/2008 and potency 99.2%. 
• Metronidazole working standard. General Medicine Company, Khartoum 
Sudan; manufacture date November/2005, expiry date November/2009 and 
potency 99.0%  
• Metronidazole benzoate working standard ,  Amiphrma Laboratories Ltd, 
Khartoum Sudan; manufacture date May/2005, expiry date May/2008 and potency 
100.2% 
• Tinidazole working standard , General Medicine Company, Khartoum 
Sudan; manufacture date October/2005, expiry date September/2010 and potency 
99.5% 
• Albendazole working standard , General Medicine Company, Khartoum 
Sudan; manufacture date May/2005, expiry date May/2010 and potency 99.0% 
• Hydrochlorthiazde working standard , Shiba Pharmaceutical, Syria; 
manufacture date May/2005, expiry date May/2008 and potency 99.2% 
• Amiloride working standard , Shiba Pharmaceutical, Syria;  manufacture 
date June /2005, expiry date May/2008 and potency 100.5%   
2.3. Selected pharmaceutical formulations  
2.3.1. Mebendazole tablets and oral suspension; AnelminTM  tablet 
manufactured by Codal Synto LTD-Cyprus, B.No.Y0815, Mf. Date 8/06, Exp. 
Date 8/010, ErizoleR tablet manufactured by Efroze Chemical Industries 
/Pakistan, B. No. D002, Mf. Date 10/05, Exp. Date 9/10, VermoxTM tablet 
manufactured by Janssen Pharmaceutical-Cilag/Belgium, AntiverTM tablet 
manufactured by Alex pharm. / Egypt, B. No. 507511, Mf. Date 5/07, Exp. Date 
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5/011 and VermoxTM oral suspension manufactured by Janssen Pharmaceutical-
Cilag/Belgium, B.No.7BB4S00, Mf. Date 2/07, Exp. Date 1/012 and ErizoleR 
oral suspension manufactured by Efroze Chemical Industries /Pakistan, B. No. 
D001, Mf. Date 9/06, Exp. Date 8/9, 
2.3.2. Albendazole tablets and oral suspension; ZentelTM tablet manufactured 
by Glaxo Wellcome Production/France, B. No. 1255, Mf. Date 3/07, Exp. Date 
3/011, AlbexR tablet manufactured by Shiba Pharmaceutical/Yemen, 
B.No.06B03B,  Mf. Date 2/06, Exp. Date 2/09 and ZentelTM suspension 
manufactured by Glaxo Wellcome Production/France, B.No.6016, Mf. Date 8/06, 
Exp. Date 8/09  ) 
2.3.3. Metronidazole tablets; AminidazoleTM tablet, manufactured by 
Amipharma laboratories Sudan, MetrozoleR tablet manufactured by Jordanian 
pharmaceutical manufacturing,  B.No.0605103, Mf. Date 5/06, Exp. Date 5/011 
and NilozoleTM tablet manufactured by Blue Nile pharmaceutical Sudan, B. No. 
03, Mf. Date 11/07, Exp. Date 11/09. 
2.3.4. Metronidazole benzoate oral suspension; AminidazoleTM oral suspension, 
manufactured by Amipharma laboratories Sudan, B.No.WMZ07095, Mf. Date 
12/07,Exp.date12/10, and FogylTM oral suspension, B. No.s1617, Mf. Date 
sep/2007, exp. Date Aug. 2009, Manufactured by Fourrts laboratories India. 
2.3.5. Tinidazole tablets;  TiniTM tablet manufactured by Codal Synto LTD/ 
Cyprus, B.No.X1108, Mf. Date 11/06, Exp. Date 11/10  , ProtogyneR tablet 
manufactured by Hayat pharmaceutical /Jordan, B. No.61033, Mf. Date 4/06, 
Exp. Date 4/09 and ProtozoleTM tablet manufactured by Medical Union 
Pharmaceutical/ Egypt, B. No. 062267, Mf. Date 9/06, Exp. Date 9/09 
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2.3.6. Hydrochlorothiazide and Amiloride Hydrochloride tablets 
UnireticR tablet manufactured by the united pharmaceutical Aman/Jordan, B. 
No.1640,  Mf. Date 7/05, Exp. Date 7/08, YostireticR tablet, manufactured by 
Amoun Pharmaceutical Co/Egypt,  B. No. 4213, Mf. Date 12/06, Exp. Date 
12/09 
2.4. Procedures 
2.4.1. Mebendazole Standard 
2.4.1.1. Spectrophotometry analysis of mebendazole standard 
2.4.1.1.1. Calibration curve of mebendazole standard 
Two weights (25 mg each) of mebendazole working standard were separately 
transferred to two 50 ml volumetric flasks; one was dissolved in 0.5M methanolic 
HCl and the other in 10 ml formic acid and completed by isopropanol to volume. 
Five ml of the first stock solution were transferred to three 50 ml volumetric 
flasks and diluted to volume using water, 0.5M methanolic HCl and methanol 
respectively. Five ml of the second stock solution were transferred to three 50 ml 
volumetric flasks and diluted to volume using water, isopropanol respectively and 
5 ml of formic acid was added to the third and the volume was completed using 
isopropanol. Well separation was obtained when using isopropanol, so 
isopropanol was used as a solvent and serial dilution was made to obtain 
concentration range (10-50µg/ml). Spectrum was recorded over the range 200-
400nm, and 2nd derivative was obtained at maximum wave length 271nm .The 
results obtained were plotted against concentration to check linearity. 
2.4.1.1.2. Assay of mebendazole dosage forms 
Ten tablets of AnelminTM , VermoxTM ,AntiverTM and ErizoleR were weighed and 
powdered. A quantity of the powder containing the equivalent of 10 mg of  
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mebendazole and an accurately weighed volume of   VermoxTM and ErizoleR oral 
suspension equivalent to 10 mg mebendazole were weighed, transferred to 50ml 
volumetric flasks , dissolved using isopropanol, and the mixture was sonicated to 
aid solubility for 15 minute. The volume was completed with isopropanol, filtered 
and the first few ml of filtrate were discarded. Five ml of filtrate were transferred 
to 50 ml volumetric flask and the volume completed with isopropanol. 
2.4.1.2. High performance liquid chromatography analysis of                                
mebendazole dosage forms 
Twenty five mg of mebendazole working standard were accurately weighed and 
transferred to 100 ml volumetric flask. Ten ml of formic acid were added and the 
mixture heated in a water bath at 50°C for 15 minutes and shaken by mechanical 
means for 5minutes. Ninety ml of methanol were added and the mixture allowed 
to cooled and diluted with methanol to volume. Five ml of this solution were 
transferred to 25-ml volumetric flask and diluted with mobile phase to volume. 
Twenty tablets of AnelminTM   VermoxTM AntiverTM and ErizoleR were accurately 
weighed and finely powdered. A portion of the powder equivalent to 50 mg 
mebendazole and a volume of  VermoxTM and ErizoleR oral suspension equivalent 
to 50 mg mebendazole were  accurately weighed and transfered to 10 ml 
volumetric flask. Five ml of formic acid were added, and the mixture was heated 
in a water bath at 50° for 15 minutes, shaken by mechanical means for one hour, 
diluted with water to volume and filtered. Five ml of the filtrate were transferred 
to 100 ml volumetric flask, diluted with a solution of formic acid in methanol 
(1:9) to volume, and mixed. Five ml of this solution was transfered to 25 ml 
volumetric flask and diluted to volume with mobile phase. 
The chromatographic procedure was carried out using as a mobile phase, with a 
flow rate 1.5 ml/minutes, a mixture of methanol and 0.05 M monobasic potassium 
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phosphate (60:40), adjusted to a pH of 5.5 with 0.1 M phosphoric acid or 1N 
sodium hydroxide. 
The liquid chromatography is equipped with a 247 nm detector and 3,9-mm×30-
cm analytical column that contained packing L1 and maintained at 30°C, (USP, 
2007). 
2.4.2. Albendazole standard 
2.4.2.1.  Spectrophotometry analysis of albendazole standard 
2.4.2.1.1. Calibration curve of albendazole standard 
Twenty five mg of albendazole working standard were accurately weighed and 
dissolved in 50 ml of 0.1M methanolic HCl. 5 ml of this solution was transferred 
to four 50 ml volumetric flasks and diluted using water, 0.1M methanolic HCl, 
0.1M HCl and methanol. Well separation was obtained when using 0.1M 
methanolic HCl and methanol, so methanol was used as a solvent and serial 
dilution was made to obtain concentration range (10-50 µg/ml). Spectrum was 
recorded over the range 200 nm-400 nm; and 2nd derivative was obtained at 330 
nm. The results obtained were plotted against concentration to check linearity. 
2.4.2.1.2. Assay of albendazole dosage forms 
Ten tablets of ZentalTM and AlbexR were weighed and powdered. A quantity of the 
powder equivalent to 20 mg albendazole and an accurately weighed volume of 
ZentalTM oral suspension (equivalent to 20 mg of albendazole) were weighed and 
transferred to 25 ml volumetric flask 15 ml of methanol were added and the 
mixture sonicated for 15 minutes, diluted to volume with methanol, mixed and 
filtered. The first ml of filtrate was discarded and 2ml of the filtrate were diluted 
to 50 ml with methanol. 
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2.4.2.2. High performance liquid chromatography analysis of albendazole 
dosage forms 
Twenty five mg of albendazole working standard were accurately weighed and 
transferred to 25 ml volumetric flask, and dissolved using acidified methanol 
(mixture of methanol and hydrochloric acid (99:1)). A volume of 5 ml of this 
solution was accurately measured and diluted to 50 ml with mobile phase. 
10 tablets of ZentalTM and AlbexR were weighed and powdered. A quantity of 
powder equivalent to 25 mg albendazole and an accurately weighted volume of 
ZentalTM oral suspension equivalent to 25 mg of albendazole were  weighed and 
transferred to 25ml volumetric flasks; 15 ml of acidified methanol were added and 
the mixture sonicated for 15 minutes, diluted to volume with acidified methanol 
mixed and filtered. The first ml of filtrate was discarded and 5ml of the filtrate 
were diluted to 50 ml with mobile phase. 
The chromatographic procedure was carried out using as a mobile phase a 
solution prepared by dissolving 11g of monobasic sodium phosphate in 800ml of 
water, and 1200 ml of methanol were added. The liquid chromatography is 
equipped with 308-nm detector and 4-mm×25-cm column that contain packing 
L1. The flow rate was 2 ml per minute; (USP, 2007)  
2.4.3. Metronidazole standard 
2.4.3.1. Spectrophotometry analysis of metronidazole standard      
2.4.3.2.1.  Calibration curve of metronidazole standard      
Twenty five mg of metronidazole working standard were accurately weighed and 
dissolved in 50 ml water. Serial dilutions were made to obtain concentration range 
(1.25-50 µg/ml). Spectrum was recorded over the range (200 nm –400 nm.). 
Maximum absorption and 1st derivative were obtained at wavelength 320 nm and 
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plotted against concentration to check linearity. The method was compared with 
the HPLC method.   
2.4.3.2.2. Assay of metronidazole dosage forms 
Twenty tablets of AmindazoleTM , MetrozoleTM and NilozolTM were weighed and 
powdered.  A weight equivalent to 25 mg of metronidazole was transferred to 100 
ml volumetric flask, 50 ml of water were added and the mixture was sonicated for 
30 minutes, cooled, completed to volume with water and filtered. The first 10 ml 
of filtrate were discarded and 2 ml of filtrate were diluted to 25 ml with water. 
Absorbance and 1st derivative at 320 nm were recoded. (Each sample was 
prepared in three different days and four repetitions in each day). 
2.4.3.1.   High performance liquid chromatography analysis of                                     
metronidazole dosage forms 
A hundred mg of metronidazole working standard were accurately weighed and 
transferred to50 ml volumetric flask dissolved in methanol. 2 ml was diluted to 10 
ml with methanol.  
Twenty tablets of AminidazolTM , MetrozoleR and NilozolTM   were weighed and 
powdered. A weight equivalent to 100 mg of metronidazole was transferred to 50 
ml volumetric flask, 5 ml of methanol were added and the mixture shaken by 
mechanical means for 30minutes.  It was completed to volume with methanol, 
filtered and the first 10 ml of filtrate was discarded. 2ml of filtrate was dilute to 10 
ml with methanol.  
The liquid chromatography was equipped with 254-nm detector and 4.6-mm ×15-
cm column that contains packing L7. The flow rate was 1ml per minute. As a 
mobile phase a mixture of water and methanol (20:80) was used; (USP, 2007) 
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2.4.4. Metronidazole benzoate standard 
2.4.4.1. Spectrophotometry analysis of metronidazole benzoate standard  
2.4.4.1.1. Calibration curve of metronidazole benzoate standard 
Twenty five mg of metronidazole benzoate working standard were accurately 
weighed, dissolved in 1 ml of dimethylformamide and completed to 50 ml with 
methanol. Serial dilutions were made to obtain concentration range (10-50 µg/ml). 
Spectrum was recorded over the range (200nm._ 400nm). Maximum absorption 
and   derivative obtained at wavelength 320 nm were plotted against concentration 
to check linearity. The method was compared with an HPLC method. 
2.4.4.1.2. Assay of metronidazole benzoate dosage forms 
A measured quantity of the AmindazoleTM and FogylTM oral suspension 
containing the equivalent of 20 mg of metronidazole was dissolved with 15 ml of 
methanol in 25ml volumetric flask; sonicated for 10 minutes, cooled and the  
volume completed with methanol, mixed  and  filtered. 2 ml of this solution were 
transferred to 50ml volumetric flask and diluted to volumes with methanol. 
Zero absorbance and 2nd derivative were carried out. Four samples from each 
preparation were prepared in the same day to study within day variation.  To study 
between day variations the analysis was repeated in three days.  
2.4.4.2. High performance liquid chromatography analysis of metronidazole 
benzoate dosage forms 
A measured quantity of the AminidazolTM and FogylTM oral suspension containing 
the equivalent of 20 mg of metronidazole was dissolved with 15 ml of methanol. 
Sufficient water was added with mixing and cooling to produce 25 ml. The 
solution was mixed and filtered. 2 ml of this solution were transferred to 25ml 
volumetric flask and diluted to volumes with methanol (60%). 62.5 mg of 
50 
 
metronidazole benzoate working standard were weighed  and transferred  to 50 ml 
volumetric flask, dissolved in 1 ml of dimethylformamide and 30 ml of methanol. 
Sufficient water was added with mixing and cooling, to produce 50 ml. 2 volumes 
were diluted to 25 volumes with methanol (60%).  
The chromatographic procedure was carried out using (a) a stainless steel column 
(25 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography, (b) a 
mobile phase consisting of a mixture of 40 volumes of a 1.25% w/v solution of 
ammonium acetate, adjusted to pH 7.0 with dilute acetic acid or dilute ammonia, 
as appropriate, and 60 volumes of methanol with a flow rate of 1.0 ml per minute 
(c) a detection wavelength of 310 nm. (BP, 2007). The analysis was repeated in 
three different days, with four repetitions in each day. 
2.4.5. Tinidazole standard 
2.4.5.1. Spectrophotometry analysis of tinidazole standard                                                
2.4.5.1.1. Calibration curve of tinidazole standard                                                
Two weights (25 mg each) of tinidazole working standard were separately 
transferred to two 50 ml volumetric flasks; one was dissolved in methanol and the 
other in 0.01M HCl. 
Five ml of the first stock solution were transferred to two 50 ml volumetric flasks 
and diluted using water and 0.01 M HCl. 5 ml of the second stock solution were 
transferred to two 50 ml volumetric flasks and diluted using water and methanol.  
Same results were obtained when using methanol and diluting with water or 
methanol, so water was used as diluting solvent and serial dilutions were made to 
obtain concentration range (10-50 µg/ml). Spectrum was recorded over the range 
200 nm-400 nm. The results obtained were plotted against concentration to check 
linearity. 
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2.4.5.1.2. Assay of tinidazole dosage forms 
Ten tablets of TiniTM   , ProtogyneR and ProtozoleTM were weighed and powdered. 
A weight equivalent to 50 mg was transferred to 50 ml volumetric flask, 30 ml of 
methanol was added and the mixture sonicated for 30 minutes, cooled, completed 
to volume by methanol and filtered. The first few ml of filtrate were discarded and 
2ml of filtrate was diluted to 50 ml with water. Absorbance and first derivative 
spectra were recorded. 
2.4.5.2. High performance liquid chromatography analysis of tinidazole dosage 
forms 
Fifty mg of tinidazole working standard accurately weighed and transferred to 50 
ml volumetric flask, dissolved in methanol and 2 ml were diluted to 25 ml with 
water.  
Ten tablets of TiniTM   , ProtogyneR and ProtozoleTM were weighed and powdered. 
A weight equivalent to 50 mg of tinidazole was transferred to 50 ml volumetric 
flask, 30 ml of methanol were added and the mixture sonicated for 30minutes, 
completed to volume with methanol and filtered. The first 10 ml of filtrate were 
discarded and 2 ml of filtrate were diluted to 25 ml with water.  
The liquid chromatography was equipped with 254-nm detector and 4.6-mm ×15-
cm column that contains packing L7. The flow rate was 1ml per minute. As a 
mobile phase a mixture of water and methanol (20:80) was used. 
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2.4.6. Hydrochlorothiazide and amiloride hydrochloride standards 
2.4.6.1. Spectrophotometry analysis of hydrochlorothiazide and amiloride 
hydrochloride standards 
2.4.6.1.1. Calibration curve of hydrochlorothiazide and amiloride  
hydrochloride standards 
• A hundred mg of hydrochlorothiazide were accurately weighed, dissolved 
in 20 ml of methanol. 4 ml of 1N HCl were added and the volume completed to 
100 ml with water. Serial dilutions were made to obtain a concentration range (50 
µg/ml -10 µg /ml). 
• Standard stock solution of amiloride hydrochloride was prepared by 
dissolving 50 mg of amiloride hydrochloride in methanol to obtain a final 
concentration of 1mg/ml. Serial dilutions were made using water to obtain 
concentration range (5µg/ml -1 µg /ml) 
• Standard stock combined solution containing hydrochlorothiazide 1mg/ml 
and amiloride hydrochloride 0.1mg/ml were prepared by dissolving 100 mg of 
hydrochlorothiazide in 20 ml of methanol and 4 ml of 1N HCl. 10 ml of amiloride 
hydrochloride from stock (0.1mg/ml) were added and the mixture diluted to 100 
ml with water. Serial dilutions were made to obtain concentration range (50 µg/ml 
-10 µg /ml) for hydrochlorothiazide and (5 µg /ml-1 µg /ml) for amiloride 
hydrochloride with water. 
The absorption spectra of both pure standard solutions and binary mixtures 
prepared at different concentrations were carried out using water as blank. 
 2nd derivative for all solutions were done. 
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Amiloride hydrochloride standard solution zero order absorption spectra gave a 
maximum peak at 364 nm, while hydrochlorothiazide gave a maximum peak at 
271nm for zero order absorption spectra and a maximum peak at 289 nm for 2nd 
derivative absorption. 
The binary mixtures 2nd derivative absorbance gave a maximum peak at 289 nm, 
while the zero order absorption gave maximum peaks at 271 nm and 364 nm, 
which by comparison with zero absorption for individual components correspond 
to hydrochlorothiazide and amiloride respectively. 
Accordingly the zero absorption at 364 nm was used for determining amiloride 
hydrochloride in pure sample and in combination with hydrochlorothiazide and 
the 2nd derivative absorbance at 289 nm was used for determination of pure 
hydrochlorothiazide and in its combination. 
The calibration curve for zero absorption spectra and 2nd derivative absorption for 
pure active substances and binary mixtures were plotted and evaluated by using 
peak to zero. 
2.4.6.1.2. Assay of Hydrochlorothiazide and Amiloride hydrochloride dosage 
forms 
Ten tablets of unireticR and yostireticR were weighed and finely powdered. An 
accurately weighed portion of the powered (equivalent to 5 mg amiloride 
hydrochloride) was transferred to 50 ml volumetric flask, 15 ml of methanol and 2 
ml of 1N hydrochloric acid were added. The mixture was sonicated for 10 
minutes, diluted with water to volume, sonicated for additional 10 minutes, mixed 
and filtered. 3 ml of the filtrate were diluted to 10 ml with water. The zero order 
absorbance spectrums at maximum 365nm and 2nd derivative at 286nm was 
recorded for determination of amiloride hydrochloride and hydrochlorothiazide 
respectively.  
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2.4.6.1.3. High performance liquid chromatography analysis of 
hydrochlorothiazide and amiloride hydrochloride dosage forms 
Fifty mg of amiloride hydrochloride were accurately weighed, transferred to 50 
ml volumetric flask and dissolved in methanol. 10 ml of this solution were 
transferred to 100 ml volumetric flask containing 100 mg of hydrochlorothiazide. 
20 ml of methanol and 4 ml of 1N hydrochloric acid were added and diluted to 
volume with water. 
Ten tablets of unireticR and yostireticR were weighed and finely powdered. An 
accurately weighed portion of the powered (equivalent to 5 mg amiloride 
hydrochloride) was transferred to 50 ml volumetric flask and 15 ml of methanol 
and 2 ml of 1N hydrochloric acid were added. The mixture was sonicated for 10 
minutes, diluted with water to volume, sonicated for additional 10 minutes, mixed 
and filtered. 
A mobile phase consisting of a mixture of water, methanol, and buffer solution 
(71:25:4) was used. The buffer solution was prepared by dissolving 136 g of 
monobasic potassium phosphate in 800 ml of water. The pH was adjusted by the 
addition of phosphoric acid to pH 3. The mixture was diluted with water to  
1000 ml. 
The flow rate was 1ml per minutes and the detection wave length 286 nm.  
A column of 3.9-mm×30-cm containing packing L1was used (USP, 2007). 
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Chapter Three 
Results and discussion 
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The application of the developed method for the different formulations is to study 
the selectivity of the method and the interference of different excipients used in 
these formulations. The results of analysis of these formulations were compared 
and validated with official HPLC methods. 
Comparisons were made with regard to developing and adopting the proposed 
methods on bases of speed, simplicity, sensitivity, selectivity, accuracy, precision, 
reproducibility, cost and ability to be employed in routine analysis of the drug. 
Statistical analysis for the results was done to study the accuracy, precision, 
repeatability and reproducibility of the developed method. 
3.1. Results of analysis of mebendazole 
3.1.1. UV derivative spectrophotometry results of mebendazole standard 
Mebendazole standard solution was analyzed using derivative spectroscopy; best 
resolution was obtained with 2nd derivative and using isopropanol as solvent. 
 
 
 
 
 
 
 
 
 
 
 
Figure (1): UV spectrums of mebendazole standard solution 
                  a) Zero absorbance spectrum 
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        b) 2nd derivative absorbance spectrum 
3.1.1.1. 2nd derivative absorbance calibration curve of mebendazole 
standard 
A calibration curve was constructed relating the concentration of mebendazole in 
a concentration range 5-50 µg/ml in isopropanol to the corresponding second 
derivative absorbance at wavelength 271 nm with a detection limit of 5µg/ml. The 
calibration curve for 2nd derivative absorbance was plotted and evaluated using 
peak to zero (figure 2) 
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Table (1): 2nd derivative spectrophotometry results for mebendazole standard 
Conc. µg/ml 2nd  derivative absorbance (271nm) 
5 0.1 
10 0.2 
20 0.36 
30 0.53 
40 0.70 
50 0.84 
 
 
             
Figure (2):  2nd derivative spectrophotometric calibration curve for 
mebendazole standard solution 
2nd derivative absorption spectrum of mebendazole standard solution in 
isopropanol gave linearity in the range 5-50 µg/ml with a correlation coefficient of 
0.998; which indicates the linearity of the method. 
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3.1.1.2. 2nd derivative spectrophotometric analysis of mebendazole dosage 
forms 
Mebendazole tablets (ErizoleR, AnelminTM, VermoxTM and  AntiverTM) and two 
oral suspensions dosage form (VermoxTM and ErizoleR) were analyzed using the 
developed method. Each brand was analyzed four times in the same day to check 
within day variation and in two different days to check between days variation. 
The results were compared with the HPLC results. 
3.1.2. High performance liquid chromatography analysis of mebendazole 
dosage forms 
Mebendazole tablets (ErizoleR, AnelminTM,VermoxTM and AntiverTM) and two oral 
suspensions dosage form (VermoxTM and ErizoleR)  were analyzed using the 
official USP HPLC method.  The analysis was carried out four times in the same 
day and in different days to check within day and between days variation 
respectively. 
 
 
 
 
 
 
 
 
 
 
Figure (3): HPLC chromatogram for mebendazole 
a) Standard chromatogram 
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b) Sample chromatogram 
 
3.1.3. Results of analysis of mebendazole dosage forms 
The developed 2nd derivative spectrophotometric method was applied to four 
different brand tablets dosage form (ErizoleR, AnelminTM, VermoxTM and 
AntiverTM) and two oral suspensions dosage form (VermoxTM and ErizoleR) and 
the results were compared with the result of the official HPLC method. 
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3.1.3.1. Results of analysis of AnelminTM tablets 
Table (2): 2nd derivative spectrophotometry results of AnelminTM tablets 
 
 
 
 
 
 
 
 
 
 
 
Calculated t-value = -0.29  
Tabulated t‐ value =3.18 (at 95%confidence) 
 
Figure (4): Comparative graph of the 2nd derivative absorption results for 
AnelminTM tablets (two days study) 
Results  Day1 % content (w/w) Day2 % content (w/w) 
1 98.3 98.3 
2 97.8 99.1 
3 98.9 98.9 
4 99.6 98.8 
Mean 98.7 98.8 
Std. deviation 0.77 0.34 
%RSD 0.79 0.35 
SEM 0.39 0.17 
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Table (3):  Results of analysis of AnelminTM tablets by HPLC 
Results 
Day1% content 
(w/w) 
Day2% content 
(w/w) 
Day 3% 
content (w/w) 
1 96.9 99.8 98.4 
2 97.6 99.2 97.1 
3 99.2 100.2 99.1 
4 98.4 98.1 99.7 
Mean 98.0 99.3 98.6 
Std. deviation 0.01 0. 01 0.01 
%RSD 1.01 0.92 1.13 
SEM 0.50 0.46 0.56 
Calculated t-values for Days (1, 2), (1, 3) and (2, 3) = -1.96, -1.1 and 0.93 
respectively; Tabulated t‐ value =3.18 (at 95%confidence)  
            
Figure (5): Comparative graph of the HPLC results for AnelminTM tablets 
(three days study) 
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Figure (6): Comparative graph between the HPLC and 2nd derivative  
absorption results for AnelminTM tablets 
 
Table (4): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results for AnelminTM tablets 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
2nd derivative 
spectrophotometry 
98.71 8 560. 200.  
HPLC 98.68 8 1.12 4 0. 
    Calculated t-value = 0.1, Tabulated t =2.36 (at 95%confidence) 
   Calculated F-value = 4, Tabulated F =4.995(at 95%confidence) 
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3.1.3.2. Results of analysis of ErizoleR tablets 
Table (5): 2nd derivative spectrophotometry results for ErizoleR tablet 
 
                     Calculated t-value = 0.88 (at 95%confidence) 
                           Tabulated t‐ value =3.18 (at 95%confidence) 
 
Figure (7): Comparative graph of the 2nd derivative spectrophotometry 
results for ErizoleR tablets (two days study) 
Results Day1 % content (w/w) Day2 % content (w/w)
1 98.5 96.8 
2 96.4 96.6 
3 96.2 96.3 
4 97.2 97.04 
Average 97.1 96.7 
Std. deviation 1.04 0.31 
%RSD 1.08 0.32 
SEM 0.52 0.16 
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       Table (6): Results of analysis of ErizoleR tablets by HPLC 
Results 
Day1%content 
(w/w) 
Day2% content 
(w/w) 
Day 3% 
content (w/w) 
1 98.8 98.2 98.3 
2 99.1 99.0 97.1 
3 98.2 99.0 98.2 
Mean 98.7 98.7 97.9 
Std. deviation 0.47 0.46 0.66 
%RSD 0.47 0.47 0.67 
SEM 270. 270. 0.38 
Calculated t-values for Days (1, 2), (1, 3) and (2, 3) = -0.15, 1.31 and 1.47 
respectively (at 95%confidence) 
               
Figure (8): Comparative graph of the HPLC results of ErizoleR                    
tablets (three days study) 
 
66 
 
               
Figure (9): Comparative graph between the HPLC and 2nd derivative 
absorption results for ErizoleR tablets 
 
Table (7): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results for ErizoleR tablets 
Results  Mean N Std. Deviation Std. Error Mean
2nd derivative 
spectrophotometry  
96.9 6 740. 260. 
HPLC 98.5 6 660. 230. 
Calculated t-value = -4.54, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 1.26, Tabulated F-value =4.995(at 95%confidence) 
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3.1.3.3. Results of analysis of VermoxTM tablets 
Table (8): 2nd derivative spectrophotometry results of VermoxTM tablets 
Results 
Day1 % 
content (w/w) 
Day2 % 
content (w/w) 
1 98.9 99.9 
2 98.6 99.1 
3 98.9 98.9 
4 98.8 99.6 
Average 98.8 99.4 
Std. deviation 0.14 0.45 
%RSD 0.14 0.45 
SEM 7.07E-02 0.23 
                  Calculated t-value = -2.64 (at 95%confidence) 
                  Tabulated t‐ value =3.18 (at 95%confidence) 
                  
Figure (10): Comparative graph of the 2nd derivative results for VermoxTM 
tablets (two days study) 
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Table (9): Results of analysis of VermoxTM tablets by HPLC 
Results 
Day1% content 
(w/w) 
Day 2% content 
(w/w) 
1 99.0 98.5 
2 99.6 99.3 
3 99.8 98.9 
4 98.2 99.0 
Average 98.9 99.2 
Std. deviation 0.32 0.72 
%RSD 0.33 0.72 
SEM 0.36 0.16 
                  Calculated t-value = 0.75 (at 95%confidence) 
                       Tabulated t‐ value =3.18 (at 95%confidence) 
 
Figure (11): Comparative graph of the HPLC results of VermoxTM tablets 
(two days study) 
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Figure (12): Comparative graph between the HPLC and 2nd derivative 
absorption results for VermoxTM tablets (two days study) 
Table (10): Mean statistical analysis of spectrophotometry and HPLC results 
for VermoxTM tablets 
 Mean N Std. Deviation Std. Error Mean 
Derivative 
spectroscopy 
99.09 8 0.44 160. 
HPLC 99.04 8 530. 190.  
 
Calculated t-value = 0.1, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 1.45, Tabulated F-value =4.995(at 95%confidence) 
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3.1.3.4. Results of analysis of AntiverTM tablets 
Table (11):2nd derivative spectrophotometry results of AِntiverTM tablets 
Results Day1 % content (w/w) Day2 % content (w/w) 
1 97.0 98.2 
2 98.0 97.5 
3 97.4 98.5 
4 98. 8 97.6 
Average 97.8 98.0 
Std. 0.75 0.45 
%RSD 0.77 0.46 
SEM 0.23 0.38 
                  Calculated t-value = 0.24 (at 95%confidence) 
                      Tabulated t‐ value =3.18 (at 95%confidence) 
 
Figure (13): Comparative graph of the 2nd derivative absorption results for 
AِntiverTM tablets (two days study) 
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Table (12): Result of analysis of AِntiverTM tablets by HPLC 
Results Day1% content (w/w) Day2% content (w/w)
1 98.5 99. 5 
2 98.5 99.0 
3 99.7 98.7 
4 99.96 99.44 
Mean 98.9 99.1 
Std. 0.58 0.37 
%RSD 0.58 0.38 
SEM 0.29 0.19 
                  Calculated t-value = -0.52 (at 95%confidence) 
                      Tabulated t‐ value =3.18 (at 95%confidence) 
 
Figure (14): Comparative graph of the HPLC results for AِntiverTM tablets  
(two days study) 
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Figure (15): Comparative graph between the HPLC and 2nd derivative 
spectrophotometry results for AِntiverTM tablets 
Table (13): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results for AِntiverTM tablets 
Results Mean N 
Std. 
Deviation 
Std. Error 
Mean 
2nd derivative 
spectrophotometry 
97.9 8 0.58 0.21 
HPLC 99.0 8 0.47 0.16 
Calculated t-value = -4.16, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 1.52, Tabulated F-value =4.995(at 95%confidence) 
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3.1.3.5. Results of analysis of ErizoleR suspension 
 Table (14): 2nd derivative spectrophotometry results for ErizoleR suspension 
Results 
Day1 % 
content (w/w) 
Day2 % 
content (w/w) 
1 94.58 95.14 
2 94.96 95.76 
3 95.46 95.01 
4 95.33 95.14 
Mean 95.08 95.26 
Std. 0.40 0.34 
%RSD 0.42 0.35 
SEM 0.20 0.17 
Calculate t-value= -0.61 (at 95% confidence) 
Tabulated t‐ value =3.18(at 95%confidence) 
                           
Figure (16): Comparative graph of the 2nd derivative spectrophotometry 
results for ErizoleR suspension (two days study) 
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  Table (15): Result of analysis of ErizoleR suspension by HPLC 
Results 
Day1% content 
(w/w) 
Day2% content 
(w/w) 
1 94.62 94.39 
2 94.83 94.66 
3 94.57 95.00 
4 95.02 95.64 
Mean 94.76 94.92 
Std. 0.21 0.54 
%RSD 0.22 0.57 
SEM 0.10 0.27 
Calculate t-value= ‐0.775 (at 95% confidence) 
Tabulated t‐ value =3.18 (at 95%confidence) 
            
Figure (17): Comparative graph of the HPLC results for ErizoleR suspension 
(two days study) 
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Figure (18): Comparative graph between the HPLC and 2nd derivative 
absorption results for ErizoleR suspension 
Table (16): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results of ErizoleR suspension 
 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
2nd  derivative 
spectrophotometery 
95.17 8 350. 130. 
HPLC 94.84 8 390. 140. 
Calculated t-value = 1.73, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 1.24, Tabulated F-value =4.995(at 95%confidence) 
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3.1.3.6. Results of analysis of VermoxTM suspension 
Table (17): 2nd derivative spectrophotometry results of VermoxTM suspension 
 
Calculate t-value= ‐0.25 (at 95% confidence) 
Tabulated t‐ value =3.18 (at 95%confidence) 
         
       
Figure (19): Comparative graph of the 2nd derivative spectrophotometry 
results for VermoxTM suspension (two days study) 
Results Day1% content (w/w) Day2% content (w/w) 
1 98.82 97.77 
2 98.82 99.08 
3 98.04 99.48 
4 98.56 98.43 
Mean 98.56 98.69 
Std. 0.37 0.75 
%RSD 0.38 0.76 
SEM 0.19 0.37 
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Table (18): Result of analysis of VermoxTM suspension by HPLC 
Results Day1% content (w/w) Day2% content (w/w)
1 97.79 98.25 
2 98.69 99.39 
3 98.13 98.57 
4 97.80 98.34 
Mean 98.10 98.64 
Std. 0.42 0.52 
%RSD 0.43 0.53 
SEM 0.21 0.26 
Calculate t-value= ‐9.18 (at 95% confidence) 
Tabulated t‐ value =3.18 (at 95%confidence) 
                   
Figure (20): Comparative graph of the HPLC results for vermoxTM 
suspension (two days study) 
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Figure (21): Comparative graph between the HPLC and 2nd derivative results 
for vermoxTM suspension (two days study) 
Table (19): Mean statistical analysis s of 2nd derivative spectrophotometry and 
HPLC results for VermoxTM suspension 
 Mean N Std. Deviation Std. Error Mean 
2nd derivative 
spectrophotometry  
98.63 8 0.55 0.2 
HPLC  98.37 8 0.53 0.19 
Calculated t-value = 1.26, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 1.08, Tabulated F-value =4.995(at 95%confidence) 
The application of the proposed method for the analysis of mebendazole in the 
form of tablets and oral suspension revealed the applicability of the method for 
these formulations without matrix interference. The results of analysis done 
whether assay, within day and between days indicate that this method is accurate. 
It was found from statistical analysis of the results that the standard error of the 
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mean for all the dosage forms was less than one which is comparable with the 
standard error of the mean for the HPLC analysis; (Miller and Miller, 1993). Tests 
for accuracy and precision were found to be not significantly different from the 
official HPLC method as shown in the tables(3,4,6,7,9,10,12,13,15,16,18 and 19), 
which also indicate the repeatability of the method. The standard deviation of all 
results  of 2nd derivative spectrophotometry confirm  that  the developed method is 
precise as all results in day1and day2  cluster within the mean. The relative 
standard deviation for all day's results was less than 2 
Table (20): The calculated t- value and F-value for 2nd derivative 
spectrophotometry and HPLC results for mebendazole dosage forms 
*Tabulated t-value=4.3, **Tabulated t-value=3.18 
 * ** Tabulated t-value=2.36, * ** tabulated F-value= 4.995 
The calculated t-value for all samples by 2nd derivative compared to the HPLC 
method is less than the tabulated one which indicates that the developed method is 
precise, accurate and reproducible. The method was also found to be selective as 
the result for the active ingredient were not affected by interference from the 
excipients as judged by comparison with the HPLC results and using different 
sample 
t-value 
2ndderivative
t-value 
HPLC 
t-value 
2ndderivative 
and HPLC 
F-value 
2ndderivative
and HPLC 
AnelminTM tablets 0.29** 2** 0.1*** 2.01*** 
ErizoleR tablets 0.88** 0.15* -4.54*** 1.27*** 
VermoxTM tablets 2.64** 0.75** 0.1*** 1.49*** 
AntiverTM tablets 0.24** 0.52** -4.16*** 1.20*** 
VermoxTMsuspension 0.61** 0.78** 1.73*** 1.08*** 
ErizoleR suspension 0.25** 0.92** 1.26*** 1.24*** 
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dosage form and different brand. The F-value was predicted from HPLC results 
and the developed method. It was found that the developed method is precise as 
the calculated F is less than tabulated one (table 21). 
3.2. Results of analysis of Albendazole 
3.2.1. UV derivative spectrophotometry results of albendazole standard 
Albendazole standard solution was analyzed using derivative spectroscopy best 
resolution was obtained with 2nd derivative. Good separation was obtained by 
dissolving albendazole standard in 0.1M methanolic HCl and diluting with 
methanol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (22): UV spectrophotometry results for albendazole standard solution 
a) Zero absorbance spectrum 
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b) 2nd derivative absorbance spectrum 
3.2.1.1. 2nd derivative absorption calibration curve of albendazole standard 
A calibration curve was constructed relating the concentration of albendazole in a 
concentration range 5-50 µg/ml to the corresponding second order derivative at 
wavelength 330 nm with a detection limit of 5 µg/ml. The calibration curve for 2nd 
derivative was plotted and evaluated using peak to zero as shown in figure (23) 
Table (21): 2nd derivative spectrophotometry results for albendazole standard 
Conc. µg/ml 2nd derivative absorbance (330 nm) 
5 0.09 
10 0.18 
20 0.37 
30 0.53 
40 0.67 
50 0.87 
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Figure (23):  2nd derivative spectrophotometric calibration curve for 
albendazole standard  
3.2.1.2. 2nd  derivative spectrophotometric analysis of albendazole tablets 
dosage form 
The developed 2nd derivative spectrophotometric method was applied for analysis 
of tablets dosage form and oral suspension. Each brand was analyzed four times in 
the day to check within day variation and in three different days to check between 
days variation. 
3.2.2. High performance liquid chromatography analysis of albendazole 
tablets dosage form 
United state pharmacopeia reversed phase HPLC method was applied for analysis 
of albendazole tablets dosage form and oral suspension. The analysis was carried 
out four times in the day and in two different days to check within day and 
between days variation respectively. 
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Figure (24): Chromatogram of albendazole solution 
a)  Standard solution chromatogram 
 
 
 
 
 
 
 
 
 
 
b) Sample solution chromatogram 
3.2.3. Results of analysis of albendazole dosage form 
Three different dosage forms (ZentilTM tablets, AlbexR tablets and ZentilTM oral 
suspension) were analyzed by the proposed 2nd derivative method and the results 
obtained were compare to the results of the HPLC method 
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3.2.3.1. Results of analysis of ZentilTM tablet 
Table (22):2nd derivative spectrophotometry results of ZentilTM tablets  
Results 
Day1% 
content w/w
Day2% 
content w/w 
Day3% 
content w/w
1 100.36 100.70 100.8 
2 100.72 100.93 101.21 
3 100.12 100.81 100.65 
4 100.36 101.16 100.35 
Mean 100.39 100.90 100.39 
Std. Deviation 0.25 0.20 0.25 
%RSD 0.25 0.20 0.25 
SEM 0.12 9.93E-02 0.18 
*t-values for Days (1, 2), (1, 
3) and (2, 3) -3.64 2.92 0.53 
    * Tabulated t-value= 3.18 (at 95 % confidence) 
        
 
Figure (25): Comparative graph of the 2ndderivative spectrophotometry 
results for ZentilTM tablets (three days study) 
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Table (23): Results of analysis of ZentilTM tablets by HPLC (two days study) 
Results  Day1% content (w/w) Day2% content (w/w)
1 100.83 99.52 
2 100.05 101.16 
3 99.46 100.86 
4 100.67 100.47 
Mean 100.25 100.51 
Std. deviation 0.63 0.71 
%RSD 0.63 0.71 
SEM 310. 360. 
*t-value -0. 41  
* Tabulated t-value = 3.18 (at 95%confidence) 
 
Figure (26): Comparative graph of the HPLC results for ZentilTM tablets 
(two days study) 
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Figure (27): Comparative graph between the 2nd derivative 
spectrophotometry and HPLC results for ZentilTM tablets (two days study) 
Table (24): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results for ZentilTM tablets 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
*t-value *F-
value 
2ndderivative 
spectrophotometry 
100.65 8 0.34 0.12 
HPLC 100.38 8 0.64 0.22 
1.25 3.54 
* Tabulated t- value =2.36, Tabulated F-value =4.995(at 95%confidence) 
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3.2.3.2. Results of analysis of AlbexR tablet 
Table (25): 2nd derivative spectrophotometry results of AlbexR tablets 
Results 
Day1% content 
(w/w) 
Day2% 
content (w/w) 
Day3% 
content (w/w) 
1 100.76 99.65 99.88 
2 100.94 99.19 99.65 
3 100.00 100.35 100.81 
4 101.04 101.28 101.65 
Mean 100.68 100.12 100.49 
Std. deviation 0.47 0.91 0.91 
%RSD 0.47 0.91 0.90 
SEM 0.24 0.46 0.45 
*t-values  
Days (1, 2), (1, 
3) and (2, 3) 
0.26 0.363 -6.788 
* Tabulated t-value= 3.18 (at 95% confidence) 
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Figure (28): Comparative graph of the 2ndderivative spectrophotometry 
results for AlbexR tablets (three days study) 
Table (26): Results of analysis of AlbexR tablets by HPLC 
Results 
Day1% 
content (w/w) 
Day2% 
 content (w/w) 
1 101.70 101.32 
2 102.81 101.06 
3 101.32 102.76 
4 102.38 102.38 
Mean 102.05 101.88 
Std. deviation 0.67 0.82 
%RSD 0.66 0.80 
SEM 0.34 410. 
*t-value 0.26-  
*Tabulated t-value = 3.18 (at 95%confidence); 
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Figure (29): Comparative graph of the HPLC results for AlbexR tablets  
(two days study) 
 
 
Figure (30): Comparative graph between the 2nd derivative 
spectrophotometery and HPLC results for AlbexR tablets (two days study) 
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Table (27): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results of AlbexR tablets 
Results Mean N 
Std. 
Deviation 
Std. Error 
Mean 
*t-
value 
*F-
value 
2nd derivative 
spectrophotometry 
100.40 8 0.74 0.26 
HPLC 101.97 8 0.70 0.25 
-9.18 1.12 
*Tabulated t- value =2.36 Tabulated F-value =4.995 (at 95%confidence) 
3.2.3.3. Results of analysis of ZentilTM oral suspension 
Table (28): 2ndderivative spectrophotometry results of ZentilTM suspension 
 
Results Day1 % content (w/w) 
Day2 % 
content (w/w) 
Day3 % 
content (w/w) 
1 99.17 100.10 100.47 
2 98.54 99.69 99.65 
3 98.45 99.27 99.30 
4 99.37 99.79 99.30 
Mean 98.88 99.71 99.68 
Std. deviation 0.46 0.34 0.55 
%RSD 0.47 0.35 0.55 
SEM 0.23 0.17 0.27 
*t-values Days 
(1, 2), (1, 3) 
and (2, 3) 
-5.44 -2.63 0.19 
*Tabulated t-value (at 95%confidence) = 3.18 
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Figure (31): Comparative graph of the 2ndderivative spectrophotometry 
results for ZentilTM suspension (three days study) 
Table (29): Result of analysis of ZentelTM suspension by HPLC 
Results  Day1% content 
(w/w) 
Day2% content 
(w/w) 
1 99.94 100.41 
2 100.33 98.67 
3 99.07 98.97 
4 99.77 99.40 
Mean 99.36 99.78 
Std. deviation 0.53 0.76 
%RSD 0.53 0.76 
SEM 0.26 0.38 
*t-value  0.93 
*Tabulated t-value = 3.18(at 95%confidence) 
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Figure (32): Comparative graph of the HPLC results for ZentilTM suspension 
(two days study) 
 
 
Figure (33): Comparative graph between the 2nd derivative spectrophotometry 
and HPLC results for ZentilTM oral suspension (two days study) 
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Table (30): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results of ZentilTM suspension (two days study) 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
t-
value 
F-
value    
2nd derivative 
spectrophotometry 
99.30 8 0.58 0.21 
HPLC 99.57 8 0.65 0.23 
-0.90 1.27 
Tabulated t- value =2.36, Tabulated F-value =4.995(at 95%confidence) 
 
From the results in tables (23, 26, and 29) the calculated %RSD was found to be 
less than 2% and the SEM was less than one for the three days results in the three 
brands which indicates the reproducibility, repeatability and accuracy respectively 
of the developed method. 
From the results of analysis of the developed 2nd derivative method (tables 23, 
26and 29) and the HPLC results (tables 24, 27 and 30) of the three brands, this 
method was found to be selective as the results of active ingredient were not 
affected by interference from the excipient.  The calculated t and F-values 
between HPLC and 2nd derivative results for the three brands dosage forms as 
shown in tables (25, 28 and 31) and the calculated t-values between days results 
of the 2nd derivative as shown in tables (23, 26 and 29) were found to be less than 
the tabulated ones. This shows the precisions of the developed method. The 
method was also found to be simple and so it can be applied in the routine 
analysis of albendazole tablets and suspension. 
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3.3. Results of analysis of metronidazole 
3.3.1. UV derivative spectrophotometry results of metronidazole standard    
Metronidazole standard solution was analyzed using derivative spectroscopy. Best 
resolution was obtained with 1st derivative. Good separation was obtained by 
dissolving metronidazole standard in water and serial dilution was made using 
water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (34): UV spectrum of metronidazole standard solution 
a) Zero absorbance spectrum 
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b) 1st derivative absorbance spectrum 
3.3.1.1. 1st derivative absorption calibration curve of metronidazole 
standard 
A calibration curve was constructed relating the concentration of metronidazole in 
a concentration range 2.5-40 µg/ml in water to the corresponding first order 
derivative at wavelength 295 nm with a detection limit of 2.5µg/ml. The 
calibration curve for 1st derivative were plotted and evaluated using peak to zero 
(figure 35) 
Table (31): 1st derivative spectrophotometry results for analysis of 
metronidazole standard 
Conc. µg/ml 1st derivative absorbance 
2.5 0.066 
5 0.12 
10 0.237 
20 0.467 
30 0.68 
40 0.927 
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Figure (35): 1st derivative spectrophotometric calibration curve for 
metronidazole standard  
 
1st derivative spectrum of metronidazole standard solution in water gave linearity 
in the range 2.5-40 µg/ml with a regression of 0.999 which indicates the 
sensitivity of the proposed method. 
3.3.1.2.  1st derivative spectrophotometric analysis of metronidazole dosage 
forms 
Three different brand dosage forms of metronidazole tablets were analyzed using 
the developed method. Each brand was analyzed four times in the day to check 
within day variation and in two different days to check between days variation.  
3.3.2. High performance liquid chromatography results of metronidazole 
dosage form 
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The official (USP, 2007) reversed phase HPLC method was applied for analysis 
of metronidazole tablets. The analysis was carried out four times in the day and in 
three different days to check within day and between days variation respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure (36) Chromatogram of metronidazole standard solution: 
a)  Standard solution chromatogram 
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b)  sample solution chromatogram 
 
3.3.3. Results of analysis of metronidazole dosage forms 
The developed 1st derivative spectrophotometric method was applied to three 
different brand tablets dosage forms (AmindazoleR, NilozoleTM and metrozoleTM ), 
the results were compared to the results of the official HPLC method . 
3.3.3.1. Results of analysis of AminidazoleR tablets 
Table (32): 1st derivative spectrophotometry results of AminidazoleR tablets 
Results  Day1 %  
content (w/w) 
Day2% 
 content (w/w)
Day3% 
content (w/w)
1 101.11 100.66 100.86 
2 100.22 100.44 101.08 
3 99.78 100.00 101.30 
4 99.34 101.51 100.65 
Mean 101.64 101.24 100.97 
Std. deviation 0.76 0.63 0.28 
%RSD 0.75 0.63 0.28 
SEM 0.38 0.32 0.14 
t-value (days  
(1,2),(1,3) and (2,3)) 
-0.96 -2.19 -0. 7 
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               *Tabulated t-value= 3.18 (at 95% confidence) 
 
 
                
Figure (37): Comparative graph of the 1st derivative absorption results for 
AminidazoleR tablets (three days study) 
Table (33): Results of analysis of AminidazoleR tablet by HPLC 
Results  Day1% content (w/w) Day2% content (w/w) 
1 101.60 101.52 
2 102.14 102.04 
3 101.18 100.15 
Mean 101.64 101.24 
Std. deviation 0.48 0.97 
%RSD 0.47 0.96 
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SEM 0.28 0.56 
*t-value 1.31 
                        *Tabulated t-value= 4.3 (at 95% confidence) 
 
 
Figure (38): Comparative graph of the HPLC results for AminidazoleR 
tablets (two days results) 
 
 
101 
 
Figure (39): Comparative graph between the 1st derivative spectrophotometry 
and HPLC results for AminidazoleR tablets (Two days study) 
 
 
Table (34): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results of AminidazoleR tablets 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
*t-
value 
*F-
value 
1st derivative 
spectrophotometry 
100.38 8 0.71 0.25 
HPLC 101.83 8 0.96 0.34 
-4.31 1.83 
*Tabulated t-value= 2.36 *tabulated F-value= 4.995 (at 95% confidence) 
3.3.3.2. Results of analysis of NilozoleTM tablets  
Table (35): 1st derivative spectrophotometry results of NilozoleTMtablets 
Results  Day1% content (w/w) 
Day2 % 
content (w/w) 
Day3 % 
 content (w/w) 
1 97.79 98.02 98.48 
2 98.01 97.80 97.84 
3 97.5 98.24 98.27 
4 97.57 98.46 98.07 
Mean 97.73 98.13 98.16 
Std. deviation 0.21 0.28 0.28 
%RSD 0.22 0.29 0.28 
SEM 0.11 0.14 0.14 
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      *Tabulated t-value= 3.18 (at 95% confidence) 
       
Figure (40): Comparative graph of the 1stderivative spectrophotometry 
results for NilozoleTM tablets (three days study) 
Table (36): Result of analysis of NilozoleTM tablet by HPLC 
Results 
Day1 % 
content (w/w) 
Day2 % 
content (w/w) 
1 98.58 97.82 
2 98.48 98.53 
3 98.56 98.32 
Mean 98.54 98.22 
Std. deviation 0.05 0.36 
%RSD 0.05154 0.37 
*t-value (days,(1,2),(1,3) 
and (2,3) 
-1.62 -2.09 -0.2 
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SEM 2.93E-02 0.21 
*t-value 1.35 
 
Figure (41): Comparative graph of the HPLC results for NilozoleTM tablets 
(two days study) 
 
 
Figure (42): Comparative graph between the 1st derivative spectrophotometry 
and HPLC results for NilozoleTM tablets (two days study) 
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Table (37): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results of NilozoleTM tablets 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
*t-
value 
*F- 
value 
1st derivative 
spectrophotometry 
97.79 6 0.20 8.13E-02 
HPLC 98.38 6 0.29 0.12 
-5.516 2.1 
*Tabulated t-test= 2.57, tabulated F-value= 5.05 (at 95% confidence) 
3.3.3.3. Results of analysis of MetrozoleR tablets  
Table (38): 1st derivative spectrophotometry results of MetrozoleR tablets 
Results 
Day1% 
content (w/w) 
Day2% 
content (w/w)
Day3%  
content (w/w) 
1 102.59 103.02 102.59 
2 101.73 102.81 103.24 
3 101.94 102.59 103.02 
4 101.70 103.24 102.81 
Mean 102.00 102.92 102.92 
Std. deviation 0.41 0.28 0.28 
%RSD 0.40 0.27 0.27 
SEM 0.26 0.12 0.19 
t- value( days 
(1,2),(1,3)and 
-3.78 -1.9 -0.5 
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(2,3)) 
         *Tabulated t-value= 3.18 (at 95% confidence) 
 
Figure (43): Comparative graph of the 1stderivative absorption results for 
MetrozoleR tablets (three days study) 
Table (39): Result of analysis of MetrozoleR tablets by HPLC 
Results 
Day1% content 
(w/w) 
Day2% content 
(w/w) 
1 104.06 104.93 
2 104.15 104.60 
3 103.98 104.81 
Mean 104.11 104.78 
Std. deviation 0.08 0.17 
%RSD 0.08 0.16 
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SEM 4.88E-02 4.88E-02 
*t-value -5.2 
                       *Tabulated t-value= 4.3 (at 95% confidence) 
   
Figure (44): Comparative graph of the HPLC results for MetrozoleR tablets 
(two days study) 
 
 
 
Figure (45): Comparative graph between the 1st derivative spectrophotometry 
and HPLC results for MetrozoleR tablets (two days study) 
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Table (40): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results of MetrozoleR tablets (two days study) 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
*t-
value 
F-
value
1st derivative 
spectrophotometry 
102.45 8 0.50 0.21 
HPLC 104.42 6 0.41 0.17 
-14.51 1.49 
*tabulated t-value= 2.78 tabulated F-value=5.05 (at 95% confidence) 
The statistical analysis of the results of assay of the three different tablet dosage 
forms showed that the developed method is accurate as the SEM of all days 
results was less than one. Repeatability and reproducibility of the developed 
method were obtained by the calculation of the %standard deviation which was 
less than 2% for all results as shown in tables (33, 36 and39). The method was 
also found to be selective as the results of analysis of the active ingredient for 
three different brands were found almost the same as the HPLC results. The 
developed 1st derivative method was also precise as the HPLC method. The F-
value for HPLC and 1st derivative results of all days was found to be less than the 
tabulated ones as shown in tables (35, 38 and 41). Calculating t-test between the 
days result of 1st derivative showed the method precision (tables 33, 36 and 39).  
This method is simple and rapid compared to the HPLC method. It is safe, 
accurate and precise compared to the British Pharmacopeia non aqueous titration 
method. 
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3.4. Results of analysis of metronidazole benzoate 
3.4.1. UV derivative spectrophotometry results of metronidazole benzoate 
standard 
Metronidazole benzoate standard solution was analyzed using derivative 
spectroscopy. Good resolution was obtained with 1st derivative. Good separation 
was obtained by dissolving metronidazole benzoate standard in 5ml of 
dimethylformamide and serial dilution was made using methanol. 
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Figure (46): UV absorbance spectrophotometry of metronidazole benzoate 
solution 
a)  Zero absorbance spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
b) 1st derivative absorbance spectrum 
3.4.1.1. 1st derivative absorbance calibration curve of metronidazole 
benzoate standard 
A calibration curve was constructed relating the concentration of metronidazole 
benzoate in a concentration range 10-50 µg/ml in methanol to the corresponding 
first order derivative at wavelength 290nm with a detection limit 5 µg/ml. The 
calibration curve for 1st derivative were plotted and evaluated using peak to zero 
Table (41): 1st derivative spectrophotometer results of metronidazole 
benzoate standard 
Conc. µg/ml 1stderivative absorbance (290 nm) 
10 0.148 
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20 0.332 
30 0.461 
40 0.611 
50 0.755 
 
Figure (47): 1st derivative spectrophotometric calibration curve for 
metronidazole benzoate standard  
 
1st derivative spectrum of metronidazole benzoate standard solution in methanol 
gave linearity in the range 10-50 µg/ml with a regression of 0.997 
3.4.1.2. 1st derivative spectrophotometric analysis of metronidazole benzoate 
oral suspension 
Two brands of metronidazole benzoate oral suspensions were analyzed using the 
developed method. Each brand was analyzed four times in the day to check within 
day variation and in two different days to check between days variation. 
3.4.2. High performance liquid chromatography analysis of metronidazole 
benzoate oral suspension 
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The official (BP, 2007) reversed phase HPLC method was applied for analysis of 
metronidazole benzoate oral suspension. The analysis was carried out four times 
in the day and in three different days to check within day and between days 
variation respectively. 
3.4.3. Results of analysis of metronidazole benzoate dosage forms 
The developed 1st derivative spectrophotometric method was applied to two 
different brands oral suspension dosage forms (AminidazoleR and FogylR 
suspension). The results were compared to the result of the official HPLC method.  
3.4.3.1. Results of analysis of FogylR oral suspension 
Table (42): 1st derivative spectrophotometry results of of FogylR oral 
suspension 
Results Day1 % content (w/w) Day2 %content (w/w) 
1 
98.66 99.49 
2 
99.04 98.24 
3 
97.81 98.26 
4 
98.05 98.48 
Mean 98.39 98.62 
Std. deviation 0.56 0.59 
%RSD 0.57 0.60 
SEM 0.30 0.28 
*t-value (95% 
confidence) 
-0.64 
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*Tabulated t-test= 3.18 
 
 
                    
Figure (48): Comparative graph of the 1stderivative spectrophotometry  
results for FogylR oral suspension (two days study) 
Table (43): Results of analysis of FogylR oral suspension by HPLC 
 
Results 
Day1% content 
(w/w) 
Day2% content 
(w/w) 
1 98.917 99.32 
2 98.31 99.51 
3 99.51 98.96 
4 99.44 99.21 
Mean 99.04 99.25 
Std. deviation 0.56 0.23 
%RSD 0.56 0.23 
SEM 0.28 0.11 
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*t-value (at 95% 
confidence) 
-0.53 
        *Tabulated t-test= 3.18 (at 95% confidence) 
 
 
Figure (49): Comparative graph of the HPLC results for FogylR oral suspension 
(Two days study) 
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  Figure (50): Comparative graph between the 1st derivative 
spectrophotometry and HPLC results for FogylR oral suspension (Two days 
study) 
 
 
Table (44): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results for FogylR oral suspension 
 Mean N Std. 
Deviation
Std. Error 
Mean 
*t-
value 
*F-
value 
1st derivative 
spectrophotometry 
98.50% 8 0.55 0.19 
HPLC 99.15% 8 0.41 0.14 
-2.21 1.8 
* Tabulated t‐ value =3.18 (at 95%confidence) 
3.4.3.2. Results of analysis of AminidazoleR oral suspension: 
Table (45): 1st derivative spectrophotometry results of AminidazoleR oral 
suspension 
Results 
Day1% 
content (w/w) 
Day2 % 
content (w/w) 
1 101.80 102.97 
2 102.28 102.45 
3 102.96 100.77 
4 102.73 102.61 
Mean 102.44 102.21 
Std. deviation 0.51 0.98 
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%RSD 0.50 0.96 
SEM 260. 490. 
*t-value (at 95 
% confidence) 
0.34  
                                    *tabulated t-value= 3.18  
 
                  
Figure (51): Comparative graph of the 1st derivative spectrophotometric 
results for AminidazoleR oral suspension (two days study) 
Table (46): Result of analysis of AminidazoleR oral suspension by HPLC 
Results 
 Day1 % 
content (w/w) 
Day2 % 
content (w/w) 
1 103.57 102.65 
2 102.10 103.34 
3 103.45 103.16 
4 101.67 102.87 
Mean 102.70 103.00 
Std. Deviation 0.96 0.31 
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%RSD 0.93 0.30 
SEM 0.48 0.15 
t-value (at 95% 
confidence) 
-0.57 
                    *tabulated t-test= 3.18 
 
Figure (52): Comparative graph of the HPLC results for AminidazoleR oral 
suspension (two days study)  
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Figure (53): Comparative graph between the 1st derivative spectrophotometry 
and HPLC results for AminidazoleR oral suspension (two days study) 
 
 
 
Table (47): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results of AminidazoleR oral suspension (two days study) 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
*t-
value
*F-
value 
1st derivative 
spectrophotometry 
102.44% 8 0.51 0.26 
HPLC 102.70% 8 0.96 0.48 
-0.43 3.54 
Metronidazole benzoate is insoluble in water while the metronidazole is soluble, 
(WHO, 2003), so the preparation of metronidazole benzoate is different from the 
metronidazole. They both absorb at the same maximum wavelength and give 
better separation with the 1st derivative as the absorption is due metronidazole 
base in both  
The developed method was found to be selective as it gives results of the active 
ingredient without the interference of the excipient. This was shown by 
comparison of the results of analysis of oral suspension by the developed method 
with the HPLC results as shown in tables (45and 48). The developed 1st derivative 
method was also accurate as the calculated SEM for all results of dosage form was 
found to be less than 1 as shown in tables (43 and 46). The developed method 
gave reproducible and repeatable results as the % relative standard deviation for 
between days results are less than 2% tables (43, 46). The precision of the method 
was studied by calculating F-test and comparing with the tabulated ones. The 
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calculated F-test between the HPLC results and the developed method results was 
found to be less than the tabulated ones which mean that the developed method 
was precise (tables 45 and 48). Within assay precision was calculated by 
calculating t-test between day's results. This method was found to be accurate, 
precise, repeatable, reproducible, selective and rapid so it can be applied in 
routine quality control analysis. 
3.6. Results of analysis of tinidazole 
3.6.1. UV derivative spectrophotometry results of tinidazole standard 
Tinidazole standard solution was analyzed using derivative spectroscopy. Best 
resolution was obtained with 1st derivative. Good separation was obtained by 
dissolving tinidazole standard in methanol and diluting with water. 
 
 
 
 
Figure (54): UV spectrum of tinidazole standard solution 
           a) Zero order absorbance spectrums 
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                 b) 1st derivative absorbance spectrum  
3.6.1.1. 1st derivative absorbance calibration curve of tinidazole standard 
A calibration curve was constructed relating the concentration of tinidazole in a 
concentration range 5-50 µg/ml to the corresponding first order derivative at 
wavelength 300 nm with a detection limit of 5 µg/ml. The calibration curve for 1st 
derivative were plotted and evaluated using peak to zero 
Table (48): 1st derivative spectrophotometry results for tinidazole standard 
Conc.( µg /ml) 1st derivative absorbance ( 300 nm) 
5 0.04 
10 0.08 
20 0.15 
30 0.23 
40 0.29 
50 0.38 
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Figure (55): 1st derivative spectrophotometric calibration curve for tinidazole 
standard  
3.6.1.2. 1st derivative spectrophotometric analysis of tinidazole tablets dosage 
forms 
The developed 1stderivative spectrophotometric method was applied for analysis 
of tablets dosage forms (three brands). Each brand was analyzed four times in the 
day to check within day variation and in different days to check between days 
variation. 
3.6.2. High performance liquid chromatography analysis 
A reversed phase HPLC method was applied for analysis of tinidazole tablets 
dosage forms. The analysis was carried four times in the day and in different days 
to check within day and between days variation respectively. 
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Figure (56): HPLC chromatogram for tinidazole solution 
          a) Standard solution chromatogram 
 
 
 
 
 
 
 
 
 
 
 
           b) Sample solution chromatogram 
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3.6.3. Results of analysis of tinidazole dosage forms 
Three different brand tablets dosage form (ProtozoleTM, TiniTM and ProtogynR) 
were analyzed by the developed 1st derivative method and the results obtained 
were compared to the result of an HPLC method 
3.6.3.1. Results of analysis of ProtozoleTM tablets 
Table (49):1st derivative spectrophotometric results of ProtozoleTM tablets 
Results 
Day1% content 
(w/w) 
Day2 % content 
(w/w) 
Day3% content 
(w/w) 
1 100.45 100.89 101.06 
2 100.23 101.34 102.12 
3 100.90 102.01 101.06 
4 100.90 100.67 100.71 
Mean 100.62 101.23 101.24 
Std. 
Deviation 0.34 0.59 0.61 
%RSD 0.34 0.58 0.60 
SEM 0.17 0.30 0.31 
     Calculated t-values for Days (1, 2), (1, 3) and (2, 3) = -01.89, -1.35 
 and -0.03 respectively; Tabulated t‐ value =2.36 (at 95%confidence)  
 
 
 
 
 
123 
 
 
Figure (57): Comparative graph of the 1stderivative spectrophotometry 
results for ProtozoleTM tablets (three days study) 
Table (50): Results of analysis of protozoleTM tablets by HPLC 
Results 
Day1% content 
(w/w) 
Day2% content 
(w/w) 
1 100.88 100.36 
2 99.69 99.30 
3 100.70 100.10 
4 100.95 99.91 
Mean 100.42 99.92 
Std. deviation 0.61 0.45 
%RSD 0.60 0.45 
SEM 0.30 0.23 
                          Calculated t- value =2.5(at 95% confidence) 
                            Tabulated t‐ value =2.36 (at 95%confidence) 
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Figure (58): Comparative graph of the HPLC results for ProtozoleTM tablets 
(two days study) 
 
             
Figure (59): Comparative graph between the 1st derivative 
spectrophotometry and HPLC results for ProtozoleTM tablets 
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Table (51): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results for ProtozoleTM tablets (two days study) 
 Mean N 
Std. 
Deviation 
Std. Error 
Mean 
1st derivative 
spectrophotometery  
100.92% 8 0.55 190. 
HPLC  100.42% 8 860. 300. 
Calculated t-value = 1.253, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 2.44, Tabulated F-value =4.995(at 95%confidence) 
3.6.3.2. Results of analysis of ProtogyneR tablets 
Table (52): 1st derivative spectrophotometry results for ProtogyneR tablets 
Results 
Day1% 
content (w/w) 
Day2%  
content (w/w) 
Day3% 
content (w/w) 
1 96.28 96.91 96.34 
2 95.21 96.48 96.34 
3 96.07 95.64 95.67 
4 95.86 95.85 97.01 
Mean 96.48 96.43 96.48 
Std. Deviation 0.46 0.58 0.55 
%RSD 0.48 0.61 0.57 
SEM 0.23 0.29 0.27 
     Calculated t-values for Days (1, 2), (1, 3) and (2, 3) = -0.98, -1.25 
 and -0.33 respectively; Tabulated t‐ value =2.36 (at 95%confidence)  
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Figure (60): Comparative graph of the 1st derivative spectrophotometry 
results for ProtogneR tablets (three days study) 
Table (53): Result of analysis of ProtogyneR tablets by HPLC 
Results Day1% content (w/w) Day2% content (w/w) 
1 96.23 96.18 
2 96.17 96.28 
3 96.72 96.60 
4 96.80 96.67 
Mean 96.48 96.43 
Std. Deviation 0.24 0.32 
%RSD 0.25 0.33 
SEM 0.165 0.12 
Calculated t-value= 0.831 
Tabulated t- value =2.36 (at 95%confidence) 
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Figure (61): Comparative graph of the HPLC results for ProtogneR tablets 
(two days study) 
 
 
              
Figure (62): Comparative graph between the 1st derivative 
spectrophotometry and HPLC results for ProtogyneR tablets 
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Table (54): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results for ProtogyneR tablets (two days study) 
 Mean N Std. Deviation Std. Error Mean
1st Derivative 
Spectrophotometry  
96.04 8 0.52 0.  1 9 
HPLC  96.46 8 0.27 9.40E-02 
Calculated t-value = -1.81, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 3.71, Tabulated F-value =4.995(at 95%confidence) 
3.6.3.3. Results of analysis of TiniTM tablet 
Table (55): 1st derivative spectrophotometry results of TiniTM tablets 
Results 
Day1%  
content (w/w) 
Day2% 
content (w/w) 
Day3%  
content (w/w) 
1 100.68 101.12 101.12 
2 100.23 100.45 101.56 
3 100.00 101.56 99.11 
4 100.45 100.67 101.11 
Mean 100.34 100.95 100.73 
Std. 
Deviation 0.29 0.49 1.10 
%RSD 0.29 0.49 1.09 
SEM 0.15 0.25 0.55 
     Calculated t-values for Days (1, 2), (1, 3) and (2, 3) = -1.90, -0.83 
 and 0.29 respectively (at 95%confidence); tabulated t-value= 3.18 
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Figure (63): Comparative graph of the 1stderivative spectrophotometry 
results for TiniTM tablets (three days study) 
Table (56): Results of analysis of TiniTM tablets by HPLC  
Results 
Day1%  
content (w/w) 
Day2%  
content (w/w) 
1 100.96 99.84 
2 101.69 100.88 
3 100.23 101.69 
4 100.26 100.15 
Mean 100.78 100.64 
Std. Deviation 0.69 0.82 
%RSD 0.60 0.82 
SEM 0.35 0.41 
                Calculated t-value =0.25(at 95%confidence);  
                Tabulated t-value = 3.18 
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Figure (64): Comparative graph of the HPLC results for TiniTM tablets 
(Two days study) 
                
Figure (65): Comparative graph between the 1st derivative spectrophotometry 
and HPLC results for TiniTM tablets 
Table (57): Mean statistical analysis of 1st derivative spectrophotometry and 
HPLC results for TiniTM tablets (two days study) 
 Mean N Std. Deviation Std. Error Mean
1st derivative 
spectrophotometry  
100.65% 8 0.50 0.18 
HPLC  100.71% 8 0.71 0.25 
Calculated t-value = -0.24, Tabulated t- value =2.36 (at 95%confidence) 
Calculated F-value = 2.02, Tabulated F-value =4.995(at 95%confidence) 
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From the results of the analysis of different brands of tindazole tablets it was 
found that the developed 1st derivative spectrophotometry method was, accurate as 
the standard error of the mean of all the dosage forms was less than one Miller 
and Miller, (1993). The method was also found to be selective. Comparing the 
assay of the tablets by the developed method with the results of assay by HPLC 
method showed that there were no differences. The % relative standard deviation 
of all days results for the tablets were less than 2% as shown in tables 50, 53 and 
56 indicating the repeatability of the developed method.  
Table (58): The calculated t- value and F-value for 1st derivative 
spectrophotometry and HPLC results of tinidazole tablets 
sample t-value 2nd 
derivative 
t-value 
HPLC 
t-value 2nd 
derivative and 
HPLC 
F-value2nd 
derivative and 
HPLC 
ProtozoleTM tablet -1.89 2.50 1.25 2.44 
ProtogyneR tablet -0.98 0.83 -1.81 3.71 
TiniTM tablet -1.90 0.25 -0.24 2.02 
 
The calculated t-values as shown in table (59) are less than the tabulated ones for 
1st derivative spectrophotometry and HPLC results. The calculated F-values are 
less than the tabulated ones as shown in table (59) which indicate that this method 
is precise and accurate 
This method was found to be simple, rapid and exclude the use of hazardous 
solvents so can be applied in routine analysis 
The develop methods were found to be accurate, precise, repeatable, reproducible, 
selective and rapid so can be applied in routine quality control analysis. 
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3.7. Results of analysis of hydrochlorothiazide and amiloride hydrochloride 
combination 
3.7.1.  UV spectrophotometery results of simultaneous determination of 
hydrochlorothiazide and amiloride hydrochloride standard 
Standard stock solution of hydrochlorothiazide (0.2 mg/ml) and amiloride 
hydrochloride (0.02 mg/ml) were prepared by dissolving the compound in 2ml of 
dimethylformamide and completing to volume with water. Serial dilutions were 
made using water to obtain a concentration range of 10µg/ml -50 µg /ml for 
hydrochlorothiazide and 1 µg /ml-5 µg /ml for amiloride hydrochloride in the 
same proportion (10:1) available in tablet dosage form in the market respectively. 
The absorption spectra and 2nd derivative of both pure standard solutions and 
binary mixtures prepared at different concentrations were carried out using water 
as blank. 
The zero order absorption spectra of amiloride hydrochloride standard solution 
gave a maximum peak at 364 nm and its 2nd derivative did not give maximum 
absorption. Hydrochlorothiazide standard solution gave maximum peaks at 
271nm and 289 nm for zero order absorption spectra and 2nd derivative 
respectively. 
The binary mixtures zero order absorption gave maximum peaks at 271nm and 
364nm. By comparison with zero absorption for individual components, these 
peaks correspond to hydrochlorothiazide and amiloride respectively. The 2nd 
derivative for binary mixtures gave maximum at 289 nm, which correspond to 
hydrochlorothiazide 
Consequently, the zero absorption at 364 nm was used for determining amiloride 
hydrochloride in pure sample and in it is combination with hydrochlorothiazide 
133 
 
and the 2nd order derivative at 289 nm was used for determination of 
hydrochlorothiazide in pure sample and in its combination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (66): Zero absorption spectrum of amiloride hydrochloride standard 
solution 
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Figure (67): UV spectrum of hydrochlorothiazide standard solution 
a) Zero absorbance spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 2nd derivative absorbance spectrum 
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3.7.2. Spectrophotometric calibration curve of amiloride hydrochloride and 
hydrochlorothiazide standard 
3.7.2.1. Zero absorption calibration curve of amiloride hydrochloride 
standard 
A calibration curve was constructed relating the concentration of amiloride 
hydrochloride in a concentration range of 1-5 µg/ml to the corresponding zero 
order absorbance at wavelength 364 nm with a detection limit of 1 µg/ml.  
Table (59): Zero absorbance spectrophotometry calibration curve of 
amiloride hydrochloride standard 
Conc. µg/ml Zero absorbance 
1 0.074 
2 0.13 
3 0.19 
4 0.25 
5 0.32 
             
Figure (68):  Spectrophotometric calibration curve for amiloride 
hydrochloride standard 
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3.7.2.2. Zero absorption calibration curve of amiloride hydrochloride 
standard in combination with hydrochlorothiazide standard 
A calibration curve was constructed relating the concentration of amiloride 
hydrochloride in a combined solution with hydrochlorothiazide. The 
concentration used were in the same proportion available in tablets in the market 
10µg/ml -50 µg /ml for hydrochlorothiazide and 1 µg /ml-5 µg /ml for amiloride 
hydrochloride. The corresponding zero absorbance at wavelength 364 nm was 
used with a detection limit of 1 µg/ml.  
Table (60): Zero absorbance spectrophotometry results for amiloride 
hydrochloride standard in combination with hydrochlorothiazide 
Conc. µg/ml Zero absorbance 
1 0.07 
2 0.13 
3 0.19 
4 0.25 
5 0.31 
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Figure (69):  Spectrophotometric calibration curve for amiloride 
hydrochloride standard in combination with hydrochlorothiazide 
 
3.7.3. 2nd derivative absorbance  calibration curve of hydrochlorothiazide 
standard 
A calibration curve was constructed relating the concentration of 
hydrochlorothiazide in a concentration range 10-50 µg/ml to the corresponding 
second order derivative at wavelength 289 nm with a detection limit of  3 µg/ml.  
Table (61): 2nd derivative spectrophotometry calibration curve results of 
hydrochlorothiazide standard solution 
Conc. µg/ml 
2ndderivative 
absorbance (289 nm) 
10 0.21 
20 0.43 
30 0.63 
40 0.84 
50 1.05 
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Figure (70):  2nd derivative spectrophotometric calibration curve for 
hydrochlorothiazide  
3.7.3.1. 2nd derivative calibration curve of hydrochlorothiazide standard in 
combination with amiloride hydrochloride 
A calibration curve was constructed relating the concentration of 
hydrochlorothiazide in a combined solution with amiloride hydrochloride (in the 
same proportion available in tablets in the market to the corresponding second 
order derivative at wavelength 289 nm (figure 71).  
Table (62): 2nd derivative spectrophotometry calibration curve results of 
hydrochlorothiazide standard in combination with amiloride HCl 
Conc. µg/ml 2ndderivative absorbance (289 nm) 
10 0.20 
20 0.40 
30 0.60 
40 0.72 
50 0.94 
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Figure (71):  2nd derivative spectrophotometric calibration curve for 
hydrochlorothiazide in combination with amiloride hydrochloride 
                                 
3.7.3.1.1. UV spectrophotometry results of hydrochlorothiazide and 
amiloride hydrochloride in tablets dosage forms 
Hydrochlorothiazide in combination with amiloride hydrochloride tablets were 
analyzed using the developed method. Each brand was analyzed four times in the 
day to check within day variation and in two different days to check between days 
variation. 
3.7.4.  High performance liquid chromatography results of analysis of 
hydrochlorothiazide  and amiloride hydrochloride in tablets dosage form 
The official (USP, 2007) reversed phase HPLC method was applied for the 
analysis of hydrochlorothiazide in combination with amiloride hydrochloride 
tablets. The analysis was carried four times in the day and in three different days 
to check within day and between days variation respectively. 
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Figure (72): Chromatogram of amiloride HCl and hydrochlorothiazide 
a) Standard solution chromatogram 
 
 
 
 
 
 
 
 
 
 
 
b) Sample solution chromatogram 
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3.7.5. Results of analysis of amiloride hydrochloride and hydrochlorothiazide in 
tablet dosage form 
The developed spectrophotometric method was applied to two different brand 
tablet dosage forms (UnireticR and YostireticR). The results were compared with 
the results of the official HPLC method. 
3.7.5.1. Results of analysis of UnireticR tablets 
Table (63): Spectrophotometry results of amiloride hydrochloride and 
hydrochlorothiazide in UnireticR tablets 
Statistic 
analysis  
Amiloride HCl             
(zero absorbance) 
Hydrochlorothiazide    
(2ndderivative absorbance) 
 Day1 % 
content w/w 
Day2 % 
content w/w 
Day1 % 
content w/w 
Day2 % 
content w/w 
1 
107.90 108.30 97.10 97.20 
2 
107.10 107.91 98.10 97.00 
3 
108.30 107.51 97.20 96.80 
4 
106.72 108.70 97.00 97.10 
Mean 107.76 108.10 97.35 97.03 
Std. 
deviation 0.72 0.51 0.51 0.17 
%RSD 0.67 0.47 0.52 0.18 
SEM 0.36 0.26 0.25 8.54E-02 
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Figure (73): Comparative graph of the zero absorbance results for amiloride 
hydrochloride in UnireticR tablet (two days study) 
 
                 
Figure (74): Comparative graph of the 2nd derivative spectrophotometry 
results for hydrochlorothiazide in UnireticR tablets (two days study) 
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Table (64): Results of analysis of UnireticR tablets by HPLC 
Statistic 
analysis 
Amiloride HCl Hydrochlorothiazide 
 
Day1 % 
content w/w 
Day2 % 
content w/w
Day1% 
content w/w 
Day2 % 
content w/w
1 109.33 109.85 99.10 97.84 
2 108.13 108.18 98.59 98.04 
3 109.38 109.58 100.50 99.86 
Mean 108.94 109.20 99.40 98.58 
Std. deviation 0.71 0.90 0.99 1.11 
%RSD 0.65 0.82 1.00 1.13 
SEM 0.41 0.52 0.57 0.64 
 
                    
Figure (75): Comparative graph of the HPLC results for amiloride 
hydrochloride in UnireticR tablets (two days study) 
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Figure (76): Comparative graph of the HPLC results for hydrochlorothiazide 
in UnireticR tablets (two days study) 
 
                     
Figure (77): Comparative graph between the zero absorbance spectrophotometry 
and HPLC results for Amiloride HCl in UnireticR tablets (two days study) 
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Figure (78): Comparative graph between the 2ndderivative spectrophotometry 
and HPLC results for Hydrochlorothiazide in UnireticR tablets  
(two days study) 
Table (65): Mean statistical analysis of spectrophotometry and HPLC results 
for Amiloride HCl in UnireticR tablets (two days study) 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
*t-
value 
*F-
value 
Zero 
absorbance 
107.71% 6 0.65 0.27 
HPLC 109.08% 6 0.74 0.30 
-3.1 1.3 
*Tabulated t-test= 2.57, Tabulated F-value= 5.05(at 95 % confidence) 
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Table (66): Mean statistical analysis of spectrophotometry and HPLC results 
for hydrochlorothiazide in UnireticR tablets (two days study) 
 Mean N Std. deviation t-value F-value 
2nd derivative 
spectrophotometry 97.19% 6 0.39 
HPLC 98.99% 6 1.04 
1.67 2.67 
 
3.7.5.2. Results of analysis of YostireticR tablets: 
Table (67): Spectrophotometry results for amiloride hydrochloride and 
hydrochlorothiazide in YostireticR tablets 
Statistical 
analysis 
Amiloride HCl             
(Zero absorbance) 
Hydrochlorothiazide        
(2nd derivative absorbance) 
 
Day1 % 
content w/w 
Day2% 
content w/w
Day1 % 
content w/w 
Day2 % 
content w/w
1 98.6 98.02 98.7 98.81 
2 98.7 98.35 97.7 98.42 
3 98.5 98.42 98.5 97.93 
4 98.0 97.52 98.0 98.02 
Mean 98.45 98.08 98.23 98.30 
Std. deviation 0.31 0.41 0.46 0.40 
%RSD 0.32 0.42 0.47 0.41 
SEM 0.16 0.20 0.23 0.20 
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Figure (79): Comparative graph of the zero absorbance results for amiloride 
hydrochloride in YostireticR tablets 
 
             
Figure (80): Comparative graph of the 2ndderivative spectrophotometry 
results for hydrochlorothiazide in YostireticR tablets 
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Table (68): Results of analysis of YostireticR tablets by HPLC 
Statistical  analysis Amiloride HCl Hydrochlorothiazide 
 Day1 % 
content w/w 
Day2 % 
content w/w
Day1 % 
content w/w 
Day2 % 
content w/w
1 98.08 98.85 97.31 98.82 
2 97.04 98.08 98.75 98.09 
3 98.10 97.86 98.13 99.18 
Mean 97.74 98.27 98.06 98.70 
Std. deviation 0.61 0.52 0.72 0.55 
%RSD 0.62 0.53 0.74 0.56 
SEM 0.35 0.30 0.42 0.32 
 
                     
  Figure (81): Comparative graph of the HPLC results for Amiloride HCl in 
YostireticR tablets 
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Figure (82): Comparative graph of the HPLC results for hydrochlorothiazide 
in YostireticR tablets 
               
 
Figure (83): Comparative graph between the zero absorbance spectrophotometry 
and HPLC results for amiloride HCl in YostireticR tablets (two days study) 
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Figure (84): Comparative graph between the 2nd derivative 
spectrophotometry and HPLC results for Hydrochlorothiazide in YostireticR 
tablets (two days study) 
Table (69): Mean Statistical analysis of HPLC and zero absorbance 
spectrophotometry results of amiloride hydrochloride in YostireticR tablets 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
t-value F-value 
Zero 
absorbance 
98.71 8 0.5592 0.1977 
HPLC 98.68 8 1.1247 0.3976 
0.099 2.01 
Tabulated t-test= 2.36, tabulated F-value=4.995 (at 95%confidence) 
Table (70): Mean statistical analysis of 2nd derivative spectrophotometry and 
HPLC results of hydrochlorothiazide in YostireticR tablets 
 Mean N Std. Deviation t-value F-value 
2nd derivative 
spectrophotometery 
98.2% 8 0.4 
HPLC 98.38 8 0.67 
1.57 1.68 
Tabulated t-test= 2.36, tabulated F-value=4.995 (at 95%confidence) 
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The developed spectrophotometric method was found to be accurate as the 
calculated standard error of the mean was found to be less than 1 as shown in 
tables 66 and 70. It was also precise as the calculated t-test between the results of 
analysis of the sample by the proposed and the official HPLC methods were found 
to be less than the calculated as shown in tables 65, 66, 69 and 70. The 
repeatability and reproducibility of the method were also studied by calculating the 
relative standard deviation for different analysis in the day and in different days 
and was found to be less than 2% as shown in tables 65 and69. By comparing the 
results of analysis of two different brands by the present method with the results of 
analysis by the official HPLC method, it was found that this method is selective. 
The precision of the developed method was determined by calculating F-value as 
shown in tables 65, 66, 69 and 70, which was found to be less than the tabulated.   
The method was found to be accurate, selective, precise, and reproducible and can 
be used in assay of combination without prior separation. It is simple and rapid, so 
it can be used in routine quality control analysis. 
 
Derivative spectroscopy has been reported Hassan et al, 2001 for the determination 
of cisapride in pharmaceutical preparations.  
Lei and Mandana, 1999 reported second derivative spectrometric determination of 
simvasatin in tablet dosage form. Ozer and Senel, 1999 applied derivative 
spectrophotometry for the determination of lisinopril in pharmaceutical 
preparations. 
Today, derivative spectroscopy allows a fresh look to be taken at previously 
unresolved or partially resolved UV-Visible problems. Obviously, the field of 
application for derivative technique is extremely wide. 
Derivative technique solve problem of overlap of peaks for e.g. the determination 
of the exact number and location of peaks in the UV-Visible spectrum of the uranyl 
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ion (UO2++) in the 330 to500 nm region. Using derivative techniques, the19 bands 
can be very easily resolved and their positions established with accuracy Skujins 
and Varian, 1986. 
Another example is the spectrum of the isomeric diazine, pyrimidine where the two 
peaks group shifted towards shorter wavelength and showed less resolved fine 
structure in the zero UV spectrums. It is possible to resolve these peaks into their 
component peaks with the derivative technique (Abdel-Hamid, 1984) 
Derivative spectrophotometry,has found significant application in clinical, forensic 
and biomedical analysis (Gill R. 1982). In forensic toxicology, the suppression of 
the absorbance from interfering substances by second–derivative 
spectrophotometry was well demonstrated in studies on amphetamine in a 
homogenised liver extract. Transformation of the zero–order spectrum to its second 
derivative using a rapid–scanning multichannel spectrophotometer permits the 
characteristically sharp benzenoid peaks of amphetamine to be detected and 
compared with an authentic standard, while the interfering background absorption 
is reduced substantially. 
 The second- and fourth–derivative method for biological background correction 
can give a ten–fold increase in the detection limit of serum paraquat in cases of 
poisoning Fell, 1981. The derivative method can be combined successfully with 
difference spectrophotometry, to give second–derivative difference spectra, in 
which enhanced discrimination against interfering substances and sharpened fine 
structural features are observed. 
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3.8. Comparison between HPLC and derivative spectrophotometry methods 
• The unambiguous characterization of most natural products and commercial 
materials by the UV-Visible spectrophotometric technique alone is seldom 
completely successful, because most substances exhibit rather broad, featureless, 
nonspecific absorption bands, particularly in the UV region. However higher 
derivative spectroscopy does offer possibilities to obtain more characteristic, 
achievable, fingerprint spectra of many substances.   
• The statistical data compiled in this work reflected non-significant differences 
between the chosen derivative method and the known stability indicating HPLC 
method. Thus, the developed methods could be considered as stability indicating. 
• The advantage of derivative spectroscopy over HPLC resides in the fact that, it 
is simpler, more rapid and inexpensive. The HPLC is a more sophisticated 
technique, UV-Vis spectrophotometry, and the later is easier to avail in poor 
countries like Sudan. The developed methods, in this work, are easier to apply for 
routine analysis without prior cleaning steps that could be a problem in case of the 
relatively expensive columns in HPLC. 
• The derivative method is suitable for analysis of grugs combination without 
prior separation. 
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4. Conclusion 
The analysis of the pharmaceutical preparation by the developed methods 
emphasizes the wide application of derivative technique and solves the problems 
of UV-Visible technique for unresolved or partially resolved substances. It is 
concluded that these methods can be used for the routine analysis in quality 
control laboratories, as these methods are simple and rapid, accurate, precise and 
not expensive.  
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5. Recommendation 
? The developed derivative spectrophotometry methods are suitable as routine 
analytical procedure for the analysis of metronidazole, albendazole, mebendazole, 
tinidazole, metronidazole benzoate, hydrochlorothiazide and amiloride 
hydrochloride in different pharmaceutical preparations. 
? Derivative methods can be alternative method to the HPLC methods in 
analysis of pharmaceutical preparations as they are simple, rapid and inexpensive 
? Further work is recommended for employing derivative methods as stability 
indicating methods for analysis of pharmaceutical preparations in stability study 
works, and applying them in the assay of drug substances in different dosage 
forms 
? Works should be extended for applying derivative methods for all other 
pharmaceuticals formulation 
?   The derivative method should be applying in the assay of  drug substance in 
different dosage forms 
? Derivative technique can be applied in different analytical areas, for natural 
substance as well as commercial substances 
?  Derivative technique should be applied for analysis of natural substance as 
well as commercial substances 
? Derivative  technique is recommended for application in clinical, 
pharmaceutical and biochemical study 
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